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ABSTRACT

Design and Application of Matrix Metalloproteinase-9-Responsive Peptide Nanostructures
by
Jiye Son

Advisor: Prof. María Contel
Co-advisor: Prof. Rein V. Ulijn

Matrix metalloproteinase (MMP)-responsive materials have been investigated since the
late 1990’s as scaffolds for tissue engineering and since then, have evolved into sophisticated
nanomaterials for cancer-targeting therapy. In this thesis titled, “Design and Application of Matrix
Metalloproteinase-9-Responsive Peptide Nanostructures,” we aim to answer the following key
questions: can MMP-responsive nanomaterials improve the efficacy of anti-cancer treatments?
How can we achieve specificity towards MMPs using nanomaterials? Finally, what are the
advantages in using peptides as building blocks to create MMP-responsive nanostructures? Each
chapter in the thesis will address one or more of the key questions and draw conclusions at the
end.
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Chapter 1
Overview

1.1. Introduction to thesis
Matrix metalloproteinase (MMP)-responsive materials have been investigated since the
late 1990’s as scaffolds for tissue engineering and since then, have evolved into sophisticated
nanomaterials popularly used for cancer-targeting therapy. In this thesis titled, “Design and
application of matrix metalloproteinase-9-responsive peptide nanostructures,” we aim to answer
the following key questions: can MMP-responsive nanomaterials improve the efficacy of anticancer treatments? How can we achieve specificity towards MMPs using nanomaterials? Finally,
what are the advantages in using peptides as building blocks to create MMP-responsive
nanostructures? Each chapter in the thesis will address one or more of the key questions and draw
conclusions at the end.
Chapter 2 will analyze literature examples to examine if MMP specificity can be better
achieved using nanomaterials. The advantages and shortcomings of MMP-responsive
nanomaterials in improving the efficacy of anti-cancer treatments will also be discussed. Chapter
3 describes the synthesis and characterization of short peptides as building blocks to form MMPresponsive nanostructures. A systematic design of the peptide sequence will be used to evaluate
important parameters in achieving MMP specificity and to regulate nanostructure morphology and
response kinetics. Chapter 4 will address a common challenge that reduces the reproducibility in
peptide self-assembly (through residual TFA), and how to rectify it. The biocompatibility and bio
application of MMP-responsive nanostructures will be examined in Chapter 5. Finally, the last
chapter will summarize the findings of this thesis and discuss future prospects.
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1.2. Hypothesis and specific aims
Nanomedicines take advantage of particle size (1-500nm) and surface properties of
nanoscale materials to accumulate selectively in the tumor microenvironment. Examples of FDAapproved nanomedicines include Doxil (pegylated liposomal doxorubicin), Abraxane (albumin
bound paclitaxel), and dozens more in clinical phase III trials. In addition to passive targeting,
nanomedicine can be designed to actively target tumor cells using various endogenous stimuli such
as pH, antigens, integrins, and enzymes that are characteristic of cancer cells. However, it is still a
challenge to design nanostructures that can respond to cancer cell specific stimuli. Part of the
challenge is the identification and realization of appropriate materials that can be fine-tuned to
have the desired chemical and physical properties. Peptides have made a significant impact in
biomedical applications due to their inherent biocompatibility and versatility in forming stable
supramolecular nanostructures with desired functionalities, as well as their potential to be fully
biodegradable (or metabolizable).
Using systematic peptide design, my hypothesis is that the morphology, size, and charge
of nanostructures can be customized to respond to MMP-9 with controlled response kinetics and
mode of action for biological applications. The specific aims of my research project are:
Aim 1: Systematic design and characterization of peptide nanostructures
Aim 2: Control of MMP-9 responsive kinetics and mode of action
Aim 3: Biocompatibility and application of peptide nanostructures using metallodrugs
The primary sequence of peptide nanostructures is the key to achieving MMP specificity, attaining
desired morphology and functionalities, and co-assembly with payloads to form stable
nanocarriers.

2

Chapter 2
Literature analysis of MMP-Responsive Nanomaterials for Targeted Therapy

Summary
Matrix metalloproteinases (MMP) are enzymes that degrade extracellular proteins and
multiple diseases, including cancer progression, are linked to their irregular overexpression and
activity. Inhibiting the enzymes using small molecules has been a challenge due to the similar
substrate binding sites of the MMPs and multiple roles they play during stages of cancer. Rather
than inhibiting them, MMP-responsive nanomaterials take advantage of the enzyme
overexpression and utilize MMP activity to trigger events that cause desired changes in the
nanomaterials. The nanomaterials can act as drug-loaded nanocarriers and respond to MMP action
to undergo different modes of responses including particle/micelle size shrinking, aggregation, and
morphology switch from biocompatible nanomaterials to cytotoxic nanofibers. By analyzing over
40 different systems described in the literature, we have formulated guiding principles in designing
MMP-responsive nanomaterials to achieve MMP specificity. The key components include
modification of the cleavable substrate and the supramolecular architecture and electrostatic
charge of the nanomaterial. Finally, we review how the different modes of response effect the rate
of payload release and the efficacy of the treatments in biological systems.

3

2.1. Introduction
Matrix metalloproteinases (MMP) are a family of enzymes that are responsible for
degrading components of the extracellular matrix and regulating extracellular cell signals for
normal cell behaviors such as turnover of tissues, angiogenesis, wound healing, etc. Thus, irregular
expression and activation of MMPs have been linked to multiple diseases including arthritis, 1
cardiovascular diseases,2 and cancer progression.3 Specifically, the upregulation of MMPs in many
types of cancer have been studied in cell culture, animal models, and in patient-derived samples.4–
9

Therefore, MMPs have become a popular target for anti-cancer therapy, either directly by

inhibiting MMP activity using small molecules, collagen peptidomimetics, etc. or indirectly by
inhibiting MMP gene expression or MMP interaction with other proteins.10 However, many of
these strategies have failed during clinical trials (Batimastat, Marimastat, CGS 27023A,
Tanomastat, etc.) and MMPs remain as unattained, highly desirable targets.11 Major reasons for
the failure include non-specific inhibition of the 21 different MMPs with similar substrate pockets
and the timing of the MMP inhibition during cancer progression, which led to broad inhibition of
MMPs, including the ones that have anti-cancer effects at specific stages of cancer.12,13 While this
lack of specificity has led the big pharmaceutical companies to focus less on investigating MMP
inhibitors, researchers continued to develop new and improved strategies to target MMPs to
address these issues, including the use of MMP-responsive nanomaterials.
A relatively new strategy in targeting MMP is to exploit the innate activity of the
proteinases, instead of inhibiting it, to trigger anti-cancer effects using nanomaterials to release
payloads (small or bio- molecule) or form cytotoxic nanofibers. This strategy could be more
advantageous because the desired anti-cancer effect will, in theory, only be triggered in areas
where MMP activity is upregulated during specific stages of cancer progression, which allows
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temporal and spatial control of the nanomaterial response. In addition, the approach incorporates
MMP substrates, and with good understanding of MMP specificity it can be optimized to be
selective towards specific MMPs.
The first MMP-responsive material was described by Jeffrey Hubbell in 1999, pertaining
the production of polyethylene glycol (PEG)-based polymer hydrogels that contained crosslinks
that could be degraded by MMP to enable cell migration.14 Specifically, the PEG-based polymers
were crosslinked with MMP-1 cleavable peptide sequence and RGD motif to form a hydrogel that
could be used as a 3D tissue scaffold, in which entrapped fibroblasts can proteolytically degrade
the gel and invade outward.15 This MMP-responsive hydrogel was subsequentially modified to
non-covalently incorporate bone morphogenetic proteins and implanted into defected rat cranium
in vivo. Within 4 weeks, localized invasion of fibroblasts and complete bone regeneration of the
defect was observed.16 Following Hubbell’s example, numerous types of MMP-degradable
hydrogels have been described for stem cell and tissue engineering, and expanded the field to
investigate nanomaterials to target MMP related diseases, including cancer.
Since these early reports, MMP-responsive materials have been developed for other
applications, including targeted delivery of small and biomolecular therapeutic agents, imaging,
phototherapy, as well as sensors to detect and quantify MMP levels in vitro and in vivo. Using
MMP-responsive materials, an ideal system could selectively engage with a specific MMP target
at the tumor site and respond at a pre-defined rate (from few hours to multiple days) to have spatial
and temporal control of the desired effect. This chapter will discuss the importance of targeting
MMPs in anti-cancer therapy and analyze literature on MMP-responsive nanomaterials for anticancer therapy. We will review different modes of MMP-triggered response that the nanomaterials
can have and evaluate which properties of the nanomaterial such as composition, size, shape,

5

charge, etc. can influence MMP targeting by directly comparing the rate of peptide hydrolysis, or
by indirect comparison in the rate of nanomaterial response such as changes in physical properties
or release of payloads. Finally, we will analyze how both the mode and rate of MMP-response in
nanomaterials can affect the targeting activity of the nanomaterial in vitro and in vivo, and
ultimately draw conclusions on guiding principles to help create MMP targeting systems that are
customized to specific needs and functionalities.

2.2. Structure and functions of matrix metalloproteinases
Matrix metalloproteinases, also called matrixins, are a family of zinc dependent
endopeptidases that degrade the extracellular matrix and communicate extracellular cell signals.
There is a total of 23 known MMPs found in humans which are either secreted from the cells or
are bound to the surface membrane (called membrane type-MMP, MT-MMP).17 Traditionally,
MMPs were grouped by their substrates, such as collagenases or gelatinases, but upon discovery
of many more substrates they are now grouped together according to their domain structures
represented in Figure 1 and are sequentially numbered. Regulation of MMP activity and expression
at the transcription and translational levels are necessary and crucial for maintaining normal
biological processes.18
All MMPs are synthesized as inactive pro-peptides or zymogens and are activated
extracellularly (except for furin-activated and secreted MMPs) when required through a “cysteine
switch” process which breaks the Cys-Zn2+ interaction between the cysteine in the pro-peptide
domain and the Zn2+ in the catalytic domain of the enzyme. Once activated, MMP activity is
regulated by a class of proteins called tissue inhibitors of metalloproteinases (TIMPs) that can form
a complex with the catalytic domain of MMP and inhibit MMP activity. Thus, the up- or down-
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regulation of MMP expression and activity have been linked with multiple diseases, including a
wide variety of cancers. Detailed descriptions of the structures and functions of MMPs have been
published widely by Hideaki Nagasse,17,18 and Table 1 summarizes the 23 human MMPs with their
common names, domain structure, substrates, and biological roles. The isoelectric points (pI) of
the MMPs are also listed which is relevant in designing electrostatically charged nanomaterials to
match the enzyme’s charge (will be discussed in Section 2.3.3.).19 The membrane types are
generally more basic, with pI values ranging from 5.96 to 9.70, compared to the secreted MMPs
which range from 5.26 to 7.73 (except MMP-12 which has pI of 8.75).

2.2.1. MMP overexpression in cancer
The role of MMPs in cancer progression has been studied since the 1980’s and has been
mainly associated with one of the six hallmarks of cancer, tissue invasion and metastasis.20 Since
then many other cancer development processes have been associated to MMPs, including cancer
cell invasion, proliferation, apoptosis, tumor angiogenesis and vasculogenesis, cell adhesion,
migration, and epithelia to mesenchymal transitions, as well as escaping the immune
surveillance.3,10 The regulation of MMPs is a complex biological process, and both down- or upregulation of MMPs have been observed based on subtypes8 and stages9 of cancer. Of the different
MMPs, MMP-2, -7, and -9 have been most widely studied for their overexpression during cancer
progression.7 Table 2 lists concentrations of MMPs measured in various cancer cell lines, mice
models, and patient derived samples quantified using ELISA or other fluorimetric assays. The
concentrations vary by cancer types and samples, but in general they range around ng/ml for MMP2 and -9, and µg/ml for MMP-7.

7

Figure 2.1. Simplified representation of domain structures that are found in 5 secreted and 3
membrane type MMPs. The pre domain guides the enzyme towards the endoplasmic reticulum,
the pro domain keeps the catalytic domain inactive until needed, and the homopexin domain is
connected to the catalytic domain by a hinge to mediate interaction with other proteins.
Fibronectin-like domains can bind to collagen, furin domains can bind to serine proteinases to
activate the enzyme, and some contain Vit = vitronectin like inserts. Membrane types contain
TM = transmembrane domain and CT = cytoplasmic domain, or GPI =
glycosylphosphatidylinositol anchoring domain, or SA = signal anchor, Cys = cysteine array, and
immunoglobulin-like anchors. Adapted from references 10 and 18.

8

Table 2.1. List of 23 human MMPs and their biological details, substrates, and roles. Adapted from references 10, 18, and 19.

9

Table 2.1. (continued)

10

Table 2.2. Concentrations of MMP-2,5,21–25 -7,26 and -95,25,27–29 in samples from non-cancerous and 10 different types of cancers.

11

Table 2.2. (continued)

12

2.3. Achieving MMP specificity using nanomaterials
MMP-responsive nanomaterials take advantage of the inherent overexpression and activity
of MMPs produced by cells to trigger a desired response in the material. These responsive
nanomaterials are made up of various building blocks, such as peptides,28,30–35 lipids,22,23,26,29,36–41
polymers,14,24,42–54 naturally derived,55–59 and inorganic27,60–62 materials that have different
chemical and physical properties. The versatility of MMP-responsive nanomaterials allow them to
be used in any biological applications that involve overexpression and activity of MMPs, including
regenerative medicine,30,31,55 targeted delivery of therapeutic21–24,27–29,32,36–41,46–48,50,52–54,56–59,62 or
imaging agents,51,60,63–65 phototherapy,61,66 and diagnostic sensors.67–70
The one shared key component in MMP-responsive nanomaterials is a peptide sequence
that can be recognized and hydrolyzed by MMP and cause a physical or chemical change in the
nanomaterial. This peptide sequence is often used as a linker to covalently link the building blocks
together or may be a structural part of the material itself, in the case of self-assembled peptides.
The MMP-cleavable sequence is typically at least 6 amino acids long in order to be recognized by
the binding site of the enzyme and is modified on the C- and N-terminus to be imbedded or attached
onto the building block. Because MMPs are highly specific enzymes, the design of MMPresponsive materials needs to be considered thoroughly in many aspects beyond the cleavable
substrate, such as the properties and functions of the nanomaterial.
For MMPs to cleave the substrate, the enzyme must first interact with the nanomaterial and
have access to the substrate before it can bind to it. Based on a simplified estimate of spherical
proteins with similar molecular weight of MMPs, a 100 nm nanoparticle is about 30-50 times
larger than the enzyme (radius of proteins with 10-100 kDa can be calculated 2.4- 3.05 nm).71 Thus
the interaction of the enzyme with the nanomaterial is completely different from its interaction
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with a monomeric peptide substrate. Therefore, both the properties of the nanomaterial and the
primary sequence of the cleavable substrate must be designed to be compatible with the targeted
MMP.
To analyze which features of the MMP-responsive materials are most relevant, we have
surveyed the literature and analyzed 41 different systems that have been published after 2010 and
the early pioneering work published by Hubbell. Table 3 lists the different material compositions,
forms, shapes, sizes (storage modulus for hydrogels), ζ-potentials, and primary sequences of the
cleavable substrate and compares them to the rate of conversion, that is the rate in which the
substrate in the nanomaterial is hydrolyzed by MMP. In Table 3, the rate of conversion is
considered to be measured directly if the authors have provided evidence showing that the peptide
substrate was cleaved over time by chromatogram or gel electrophoresis. It is considered to be an
indirect measurement if the authors reported changes in the nanomaterial as a response to the MMP
action over time, such as changes in size, rheology or weight % for gels, ζ-potential, or drug release
profiles. This distinction is important because the rate and degree of the response in the
nanomaterial does not always correlate with the rate or the amount of substrate cleaved by MMP.
Lastly, measurements are considered to be relevant if the authors only showed the performance of
the nanomaterial in vitro or in vivo. In addition, while most of the conversion rates are measured
by incubating MMP with the nanomaterial, some rates are measured on the isolated cleavable
substrate, which is not comparable since the substrate is in an entirely different molecular context
(size, surface properties, etc.) when packaged into the nanomaterial. The molecular context of
cleavable-substrate is an important factor to distinguish in comparing the different MMPresponsive materials.
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Through analyzing the rates of conversion with the properties of the nanomaterials, we
have identified 3 key factors that can enhance the nanomaterial and enzyme interaction and
specificity towards the targeted MMP as illustrated in Figure 2. First and foremost, the primary
sequence of the substrate must be specific for the enzyme to recognize it and subtle changes in the
amino acids or terminal modification of the primary sequence can alter the cleavage site. Second,
the morphology of the nanostructure must allow MMPs to access the substrate, and the
supramolecular organization of the substrate can also target specific MMPs. Lastly, by either
matching or mis-matching electrostatic interactions, the short-range interaction between the
nanoparticle and the enzyme can be tuned.

15

Figure 2.2. Three key factors to achieve MMP specificity using nanomaterials. (1) Modification
of the primary sequence can shift the cleavage site of the peptide and slow down the rate of
hydrolysis.77,78 Based on the supramolecular structure31,33,56 (2) and electrostatic charge31,36 (3) of
the nanomaterial, specificity towards different MMPs can be achieved: β-sheet fibers can be
cleaved by MMP-13 (green) but not by MMP-9 (pink), and cationic nanoparticles are readily
cleaved by more negatively charged MMP-2 (red) in comparison to the neutral charged MMP-7
(blue).
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Table 2.3. List of MMP-responsive hydrogels and nanomaterials categorized by building block material.

17

Table 2.3. (continued)

18

Table 2.3. (continued)

19

Table 2.3. (continued)

20

2.3.1. Sequence specificity
The amino acid residues in the MMP-cleavable substrate are labeled by the number of
positions starting from the scissile bond (bond between P1 and P1’) and are labeled P1 through P6
towards the N terminus, and P1’ through P6’ towards the C terminus. Understanding substrate
specificity of this family of enzymes can elucidate the functions of specific MMPs,72 and help to
design more specific inhibitors.73 According to MEROPS database, over 7,600 MMP-cleavable
substrates have been observed and recorded.74 In addition to natural substrates, many engineered
sequences have been identified using various high throughput techniques such as phage display,75
oriented peptide library method,76 and proteomic identification of protease cleavage site (PICS).77
Although MMPs are highly specific enzymes, the general consensus sequence found in the
database are similar among MMPs, with Pro in P1, Gly in P3, and Leu in P1’ being the hallmark
of MMP substrates. This could be partly due to a bias towards working with sequences that has
already been tested and are copied by other researchers. A thorough examination by Overall et al.
in 2015, revealed that of 112 P1-P1’ cleavages reported for MMP-1, -2, -3, -7, -8, -9, -12, -13, and
-14 in MEROPS database, only 79 cleavages were unique, and only 5 sequences contained both
Pro in P1 and Leu in P1’.77 The authors investigated the substrate specificity of MMPs using
FRET-based peptides by conjugating a fluorophore, Mca (7-methoxycoumarin-4-acetic acid Nsuccinimidyl ester), on the N terminus, and a quencher, Dpa (dipicrylamine), on the C terminal
end of P1’ residue (Figure 2A). The MMP cleavage of the peptides was analyzed by measuring
the recovered fluorescence of Mca over time (Figure 2B). In comparison to the general consensus
PLG↓L peptide, PLN↓L was cleaved 2.5 times faster by MMP-1 and PAG↓L was cleaved 2 times
faster by MMP-2 and 0.25 times faster by MMP-3 (Figure 2B). Clearly, beyond the general
consensus sequence, the primary sequence can be tailored to target specific MMPs.
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Figure 2.3. Investigation of substrate specificity of MMPs using FRET-based peptides. A)
Chemical structure of the FRET-based peptides (Mca fluorophore and Dpa quencher). B)
Recovered fluorescence of Mca over time. Adapted from ref 77.
However, MMP-responsive nanomaterials require the enzyme to interact with the insoluble
nanomaterial and not just the free peptide molecules. MMP-cleavable substrates are typically
covalently modified on the C and the N terminus of the peptides to act as linkers for block-copolymers or they are used to attach functional moieties on the surface of the nanomaterial, like
targeting ligands. This modification of the peptide can have significant impact on the enzyme
recognition and hydrolysis of the cleavage site. The Bing Xu group has observed that covalent
modifications with hydrophobic residues of peptides PLGLRSK and PLSLRSK on the N terminus
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can shift the cleavage site and change the rate of hydrolysis by MMP-9.78 In this study the two
sequences were systematically modified by adding one or two phenylalanine residues on the N
terminus followed by capping the terminus with acetyl, fluorenylmethyloxycarbonyl (Fmoc),
pyrene, or naphthalene group. They observed that the cleavage site of unmodified peptide
(PLGL↓RSK) shifted to PL↓GLRSK with the addition of one or two Phe residues, both with and
without the capping groups, and the rate of hydrolysis decreased with increasing hydrophobicity
of the capping group (100% conversion for uncapped peptides, 60% conversion for naphthalene
capped peptides, and 30% conversion for Fmoc capped peptides in 72 h). This shows that even a
small modification of length and N terminal substitution can lead to different products and
conversion rates. Therefore, certainly more than the primary sequence of the substrate needs to be
considered in designing MMP-responsive materials.

2.3.2. Supramolelcular specificity
The family of MMPs can essentially degrade all components of the extracellular matrix,
ranging from highly ordered proteins such as helical collagen fibers to smaller proteins such as
fibronectin or gelatin (Table 1). Traditionally, MMPs were named after their common substrates
for example, MMP-1, -8, and -13 are also called collagenase 1, 2, and 3, respectively, and MMP2 and -9 are called gelatinase A and B, respectively. As the names suggest, MMPs have different
roles in tissue remodeling, which require them to have specific interaction with their substrates.
For instance, MMP-2 and -9 has been reported to bind to native type I collagen but cannot cleave
it until it is in the denatured gelatin form, whereas MMP-1 can easily digest the collagen fiber.79
Therefore, in addition to the primary sequence, the topology or the supramolecular structure of the
substrate must also be appropriate for the targeted MMP.
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Figure 2.4. MMP-13-responsive β-hairpin peptide hydrogels. A) Cartoon representation and B)
amino acid sequence of self-assembling β-hairpin nanofiber hydrogels. C) The β-hairpin peptide
fibers are hydrolyzed by MMP-13 and not by MMP-3. The rate of hydrogel degradation is more
dependent on the rigidity of the gel than the substrate sequence. Adapted from reference 31.

This structural specificity was demonstrated by Schneider et al. using MMP-13 responsive
β-hairpin peptide hydrogels (Figure 4A).31 These peptides contain two proline residues in the
middle of repeating IKV units to create a bend for the β-hairpin structure, and the second proline
was used to insert the MMP-cleavable substrate PTG↓X, where X = Leu, Ile, Phe, and Ala (Figure
4B). When β-hairpin peptide hydrogels were incubated with 80 nM of MMP-13 for 14 days, 3265% hydrogel degradation was observed, whereas no degradation was observed when incubated
with 40 or 400 nM of MMP-3 for 14 days (Figure 4C). Based on the sequence, both MMPs should
be able to cleave PTG↓X, however, the densely packed β-hairpin peptide fibers in the hydrogel
was only degraded by MMP-13 that naturally digests collagen fibers and not by MMP-3 which
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digests sheet-like structures such as the collagen IV, perlecan, etc. in the basement membrane
(Table 1). In addition, the rate of conversion in MMP-13 degradation of the hydrogel was also
dependent on the structural topology of the gel. According to the sequence specificity, the expected
rate of PTG↓X hydrolysis should have followed X = Leu > Ile, Phe > Ala. However, the observed
order of degradation was X = Phe (65%) > Leu (58%) > Ile (44%) > Ala (32%), due to the low
rigidity and larger pores of the Phe containing hydrogel which allows MMP-13 to penetrate gel
faster (Figure 4C). This study shows that the morphology of the peptide fiber can be designed to
target specific MMPs and the degree of crosslinks in the fiber network can be manipulated to
control the rate of hydrogel degradation.
A study by Ghandehari et al. demonstrated that the location of MMP-cleavable substrate
in the nanostructure can also control the rate of degradation (Figure 5A).56 In this study, silk elastin
polymers (silk-elastin-lysin elastin-silk motif) were modified with MMP-2 cleavable substrate
(GPQGIFGQ) imbedded in 1) between the silk and elastin blocks, 2) within the elastin block, or
3) within the silk block (Figure 5C). When a low concentration of 1 mg/ml of the MMP-responsive
silk polymer was incubated in the soluble form with 40 nM of MMP-2, the three modified
polymers were all digested 100% within 20-30 min. However, when 4% weight silk polymer
hydrogel was incubated with 40 nM of MMP-2 for 14 days, different amount of digested and
undigested polymers was released from the hydrogel (Figure 5B). Higher ratio of digested vs.
undigested released polymer was observed when the MMP-cleavable substrate was placed
between the silk and the elastin blocks, followed by the substrate imbedded within the elastin
block, and the substrate imbedded within the silk block had the lowest ratio of digested polymer.
This is because the silk block (GAGAGS) is part of the major structural component, and the
substrate is more accessible in the block junctions and in the elastin block (GVGVP).
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Figure 2.5. MMP-2-responsive silk elastin polymer hydrogels. A) Cartoon representation and B)
amino acid sequence of self-assembling silk elastin nanofiber hydrogels. C) The placement of the
MMP-2 cleavable sequence within the silk elastin polymer dictates the rate of hydrogel
degradation. Adapted from ref 56.

The two previous examples by Schneider and Ghandehari groups altered the amino acid
sequence and the placement of the cleavable substrate in the hydrogel to manipulate the rate of gel
degradation and MMP specificity. Next, we discuss an example that will be discussed in detail in
Chapter 3 to demonstrate that the morphology and the accessibility of the substrate in peptide
nanostructures that do not gel can also be manipulated to control the rate of MMP hydrolysis.33
Twelve amphiphilic peptides with diphenylalanine hydrophobic end and either lysine or aspartic
acid containing hydrophilic end were systematically modified using MMP-9 cleavable PXG↓LXG
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or AXG↓LXG motif in the center. The peptides were self-assembled at 1 mM and incubated with
100 ng/ml of MMP-9 for 96 hours. We observed that among PXG↓LXG containing peptides,
spherical micelles (100% in 48 h) were cleaved faster or at the rate as worm-like micelles (90% at
96 h). In AXG↓LXG containing peptides, the higher rigidity of the peptide backbone contributed
to higher ordered assemblies which slowed down the enzyme cleavage (from 60% to 10% in 96
h), and MMP-9 was unable to digest peptides that formed anti-parallel β-sheet fibers.
Using nanomaterials allow incorporation of more features, in addition to substrate
specificity, to target specific MMPs and manipulate the rate of enzyme cleavage. By changing the
amino acid sequence or the placement of MMP-cleavable substrate, the supramolecular structure
and properties of the materials can be modified and play a large role in MMP specificity.

2.3.2. Electrostatic specificity
Electrostatic specificity may be one of the simplest ways to target enzymes but is often
overlooked in meeting MMP specificity. The substrate binding pockets of MMPs are suited for
hydrophobic interactions and the main focus has been on aromatic and aliphatic residues of the
cleavable substrate. However, as emphasized in this literature analysis chapter, the short-range
interaction of the MMP and the nanomaterial is as important as the sequence of the cleavable
substrate. The electrostatic charge of the nanomaterials can be readily tuned to enhance or block
enzyme engagement and can also be used to target specific MMPs. The isoelectric points (pI) of
MMPs were computed by Rani et al. using ExPASy’s ProtParam tool and range broadly from 5.26
to 9.94 (Table 1).19 In addition, the pI of MMPs can differ by isoform and charge variants. Using
2D isoelectric focusing, Riccio et al. measured pI of 4.1-4.6 for several charge variants of 92 kDa
pro-MMP-9 and 82 kDa activated MMP-9, and 6 different charge variants of 65 kDa MMP-9 with
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pI ranging from 4.82-5.15.80 Using this information, the nanomaterials be designed to have same
or opposite charge to repel or recruit specific MMPs, respectively, and to control the rate of enzyme
cleavage.
In our aforementioned work (Chapter 3), the 12 different MMP-9 responsive selfassembling peptides were systematically modified to have either PXG↓LXG or AXG↓LXG motif
and positive or negative charge using lysine or aspartic acid residues, respectively. As expected,
the cationic peptides were readily cleaved by MMP-9 whereas the analogous anionic peptide had
very low conversion (2.5% in 96 h) or were not cleaved at all. This was observed for both spherical
and worm-like micelle peptide nanostructures. This electrostatic (mis) matching of charges
between nanomaterial and MMPs is a simple yet powerful technique to enhance or prevent enzyme
cleavage.
In addition to the rate of MMP cleavage, electrostatic specificity can be utilized to target a
specific MMP. Ahn et al. have designed a FRET-like system using gold nanorod particles coated
with an MMP-cleavable substrate (GPLGVRGC) conjugated to Cy 5.5., a positively charged nearinfrared dye.61 The cleavage of the substrate was monitored by recovered fluorescence of Cy 5.5.
dye. After 2-hour incubation period with different MMPs, the fluorescence was recovered 8.2
times with MMP-9, 7.8 times incubated with MMP-2, 6.6 times with either MMP-3 or -13, and
3.7 times with MMP-7. The authors recognized this selectivity but did not comment on the reasons
underpinning it. Our speculation is that the electrostatic interaction of the modified cationic gold
nanorods and the MMPs were favorable for anionic MMP-2, -3 -9, and -13 which have pI of 5.26
- 5.77. On the other hand, the pI of MMP-7 is 7.73, which makes it almost neutral at physiological
pH and least likely to be recruited by the cationic gold nanorod.
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Using (mis) matching electrostatic interactions between the enzyme and the
nanostructures, the enzyme cleavage rate and specificity can be controlled. In Table 3, there are
nanomaterials with negative zeta potentials that are cleaved by MMP-2 characterized by
Torchillini and Zhu groups, however, the rate of conversion was measured on the isolated
cleavable substrate and not on the anionic nanomaterial, or was indirectly measured based on
payload release. Therefore, these results cannot be quantitatively compared because the rate of
substrate cleavage is different when isolated vs. as part of the nanomaterial (as discussed
previously in section 2.3.2.) and does not equal to the rate of payload release. Before comparing
the rate of payload release to the rate of nanomaterial response, we will first discuss the typical
types of MMP-responsive changes that nanomaterials have.

2.4. MMP-triggered modes of response for targeted anti-cancer therapy
Inhibition of MMPs using small molecular compounds or macro biomolecules for anticancer therapy has failed in the past mainly due to the similar substrate binding site of multiple
MMPs as well as the varying expression of MMPs during various stages of cancer development.1113

Instead of inhibiting the MMP action, MMP-responsive nanomaterials are designed to take

advantage of the inherent overexpression and activity of MMPs to trigger a response in the
nanomaterial which allows spatial and temporal control of the anti-cancer activity. As discussed
in the previous Section 2.2., nanomaterials provide a versatile platform to tune the specificity
towards an individual MMP using modification of the MMP-cleavable substrate and the
morphology and charge of the nanomaterials.
In this section, 12 different MMP-responsive nanomaterials which were used for anticancer therapy, are described have been categorized into 4 different modes of responses: 1) particle
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shrinkage, 2) particle aggregation, 3) nanofiber formation, and 4) de-PEGylation of the
nanomaterial (Figure 6 and Table 4). Following the nanomaterial’s response, the anti-cancer
activity is achieved either by releasing therapeutic small molecules from bio-compatible
nanocarriers, or by switching morphology into nanofibers which can themselves have a therapeutic
effect. As we review the different categories, we will analyze how the different modes of response
can affect the rate of payload release and influence the bio-activities in vitro and/or in vivo.

Figure 2.6. MMP-triggered modes of response for anti-cancer therapy. As a response to MMP
hydrolysis of the substrate in the nanomaterial, the nanomaterial can 1) shrink in size,27,52,59,60 2)
aggregate,39,46,48 3) switch into cytotoxic nanofibers,26,28 or 4) reveal a functional moiety in the
nanomaterial without changing in size.40,41,47
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Table 2.4. MMP-triggered modes of response for anti-cancer therapy.

31

2.4.1. Size shrinking
Nanomaterials that are 100-200 nm in size can have enhanced accumulation in the tumor
microenvironment, but this accumulation is limited to the periphery edge of the tumor.81 It has
been proposed that by using nanomaterials that can shrink into smaller particles or release small
particles in response to MMP cleavage, it allows the shrunken 10-40 nm particles to penetrate the
interstitial tumor space. Fukumura et al. have used this strategy and decorated the surface of gelatin
nanoparticles with quantum dots to form 98 nm nanoparticles (Figure 7A).60 After incubating the
particles with MMP-2, 90% quantum dots (10 nm) were released from the gelatin particles in 12
hours (Figure 7B). When the MMP-responsive gelatin nanoparticles and comparable nonresponsive silica particles decorated with quantum dots were directly injected into tumors in vivo,
the quantum dots released from the gelatin particle had diffused 300 µm from the injection site,
whereas the quantum dots on the silica particle remained concentrated in the initial injection
location (Figure 7C). This example demonstrated a proof-of-concept that the MMP-triggered
release of quantum dots allowed deeper penetration into the solid tumor mass, which could
potentially be replaced by 10 nm nanocarrier of cancer therapeutics.
In another system, Kizilel et al. developed magnetic iron oxide particles coated with MMPcleavable acrylate-PEG polymer loaded with doxorubicin (Figure 8A).27 These 210 nm particles
shrunk into 31 nm particles after 1 day of incubation with collagenase (bacterial equivalent of
MMP) (Figure 8B). Interestingly, this size shrinkage did not trigger an increase in doxorubicin
(DOX) release until day 3. At day 4, 60% of doxorubicin was released from the particles that were
incubated with collagenase, in comparison to the 36% released without collagenase. Our
speculation is that although the nanoparticle’s size was responsive to the enzymatic cleavage of
the polymer coating, the rate of payload release is not simultaneously triggered by cleavage of the
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enzyme substrate, likely because the drugs are still embedded in the polymer coating and continues
to degrade in solution over time. The DOX-loaded MMP-responsive nanoparticles were
internalized by HeLa cells 11 times more than non-responsive or bare iron oxide particles in vitro
(Figure 8C). In addition, the drug-loaded nanoparticle displayed time-dependent activity in which
it was less cytotoxic to HeLa cells than free doxorubicin at 24 and 48 h, but more cytotoxic at 72
h incubation, in agreement with the release rate of DOX from the nanoparticle. The two examples
by Kizilel et al. and Fukumura et al. demonstrated that MMP-triggered shrunken nanoparticles can
have enhanced internalization by cells in vitro and penetration in solid tumors in vivo, in
comparison to non-responsive (not shrunken) nanoparticles.

Figure 2.7. MMP-2-responsive size shrinking gelatin nanoparticles. (A) Cartoon representation
and (B) experimental measurement of 10 nm quantum dots being released from 100 nm gelatin
nanoparticles upon incubation with MMP-2. (C) The quantum dots from MMP-responsive gelatin
particles were able to penetrate throughout the solid tumor in vivo, whereas the quantum dots from
non-responsive silica particles stayed localized. Scale bar 100 µm. Adapted from ref 60.
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Figure 2.8. MMP-responsive size shrinking magnetic iron oxide nanoparticles. (A) Cartoon
representation and (B) experimental measurement of 200 nm polymer coated particles shrinking
to 30 nm after incubation with collagenase. (C) Doxorubicin from dox-loaded MMP-responsive
nanoparticles were internalized 11 times more than non-responsive particles. Scale bar 10 µm.
Adapted from ref 27.

2.4.2. Induced aggregation
Nanomaterials can increase the accumulation in the tumor site as discussed in the previous
section and can also increase retention of the material by preventing it from diffusing back into the
bloodstream. In this strategy, 20-80 nm particles enter the periphery of the tumor and aggregate
upon MMP action to stay immobilized around the tumor tissue. Gianneschi et al. have developed
paclitaxel conjugated block-co-polymers using MMP-cleavable substrate (GPLG↓LAGGERDG)
as linkers to form 20 nm spherical particles (Figure 9A-B).46 When the substrate was cleaved by
MMP-12, the amphiphilic balance of the polymer is altered, 95% of particles aggregated into 4001000 nm in 4 hours (Figure 9C). When treated in vivo, the tumor growth inhibition of 15 mg/kg
paclitaxel in the MMP-responsive nanomaterial was slightly lower than that of free paclitaxel
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(Figure 9D), however, the systematic toxicity was much lower, and the maximum tolerated dose
was 15 times higher than that of free paclitaxel (Figure 9E).

Figure 2.9. MMP-12-induced aggregating polymer nanoparticles. (A) Cartoon representation and
TEM images of (B) 20 nm particles aggregating into (C) 400-1000 nm aggregates upon MMP
action. (D) Inhibition of tumor growth by paclitaxel-loaded MMP-responsive nanoparticle was
lower than free paclitaxel but, (E) the systematic toxicity much lower than free paclitaxel. Adapted
from ref 46.

MMP-induced aggregating micelles were developed by Zhu et al. using liposomes
conjugated to PEG via a MMP-2 cleavable linker (GPLGIAGQ) to encapsulate paclitaxel.39 After
2 hour incubation period with collagenase, the initial 33 nm spherical liposomes aggregated into
818 nm. In this system, hydrolysis of MMP-2 cleavable linker separates the lipid and the PEG
building blocks causing the post-cleavage hydrophobic lipid to aggregate while the released
hydrophilic PEG is solubilized. After 4-hour incubation period, 55% of the payload was released,
in comparison to 30% released without collagenase. When tested in vitro, the IC50 of paclitaxel
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loaded MMP-responsive liposomes were ten folds lower than free drug in paclitaxel-resistant cell
lines, MDA-MB-231 and NCI/ADR-RES (5-6 µM vs. 45-34 µM) due to increased uptake of the
drugs, but was higher in drug sensitive cell line, A549 (0.042 µM vs. 0.008 µM). In this system,
the destabilization of the micelles induced increased paclitaxel release and was more cytotoxic to
paclitaxel-resistant cells in vitro.

2.4.3. Cytotoxic amyloid-like nanofibers
Enzymatically triggered formation of cytotoxic nanofibers is an emerging field in anticancer therapy. This mode of response is extensively researched by Bing Xu’s group that use
phosphorylated precursors to form cytotoxic fibers upon dephosphorylation by alkaline
phosphatases overexpressed in cancer cells.82 Likewise, MMP-responsive precursors can also form
cytotoxic nanofibers upon MMP-cleavage. Maruyama et al. designed lipopeptides that can be
cleaved by MMP-7 and form nanofibers with high gelation propensity as a response (Figure
10A).26 The amphiphilic lipopeptides form 20 nm spherical micelles and when incubated with
MMP-7, the lipid portion of the cleaved product self-assembles into fibers within 1 hour (Figure
10B). These fibers caused selective toxicity to cells in vitro, that correlated with the amount of
MMP-7 produced by the cancer cells and were non-toxic to normal cells with low concentrations
of MMP-7 (Figure 2.10.C).
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Figure 2.10. MMP-7-triggered formation of cytotoxic lipopeptide nanofibers. (A) Cartoon
representation and molecular structure of the lipopeptide that switch morphology from (B)
spherical micelles to nanofibers upon MMP-7 hydrolysis (TEM images, scale bar left 50 µm;
right 100 µm). (C) The cytotoxicity of the nanofibers increases in cell lines that have high
concentrations of MMP-7. Adapted from ref 26.

Our group has also demonstrated that MMP-9-triggered formation of nanofibers has anticancer properties in vitro and in vivo.28 In this system, 200 nm spherical peptide micelles were
used to co-assemble with doxorubicin and cleaved by MMP-9 to form cytotoxic nanofibers (Figure
11A). In 96 hours, 60% of the peptide (GFFLGL↓DD) was cleaved by MMP-9 and formed bundles
of fiber (Figure 11B). The co-assembled doxorubicin was more cytotoxic in vitro and inhibited
tumor growth more than free doxorubicin in vivo. Remarkably, the peptide alone displayed similar
tumor growth inhibition effects as doxorubicin alone (Figure 11C).
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Figure 2.11. MMP-9-triggered formation of doxorubicin-loaded peptide nanofibers. (A) Cartoon
representation and molecular structure of the peptide micelles that form (B) fiber bundles upon
MMP-9 hydrolysis (AFM images). (C) Tumor growth inhibition of peptide nanofibers (red) is
comparable to free doxorubicin (yellow) and is significantly improved using the co-assembled
drug-loaded peptide nanocarriers (orange). Adapted from ref 28.

2.4.4. Activation by de-PEGylation
Polyethylene glycol or PEG is a hydrophilic polymer block often used as a coating to
solvate nanoparticles. In biological applications, it is popularly used as a “stealth” material because
macrophages are less likely to detect nanomaterials that are coated in PEG. In previous examples,
removal of PEG groups caused a change in the amphiphilic balance of the building blocks and
caused the material to aggregate or revealed smaller inorganic particles beneath the PEG layer. In
this category, unlike the example discussed above, the removal of PEG groups from the
nanomaterials does not cause a dramatic change in the size of the nanomaterials. On the contrary,
these materials are designed to maintain their shapes and sizes after the PEG cleavage. This allows
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the nanomaterials to maintain their pre-designed features while revealing the functional ligands
that were shielded by PEG.
Zhu et al. have developed MMP-responsive polymer lipid conjugate building blocks using
PEG and phophoethanolamine (PE) conjugated by MMP-cleavable linker (GPLG↓IAGQ) and/or
a trans-activating transcriptional activator (TAT) peptide that can form paclitaxel-loaded micelles.
Two paclitaxel-loaded MMP-responsive micelles were made using PEG2k-GPLG↓IAGQ-TATPEG1k-PE or PEG2k-GPLG↓IAGQ-TAT-PE and incubated with 50 µg/ml collagenase IV. In 2
hours, micelles made of PEG2k-GPLG↓IAGQ-TAT-PE aggregated from 58 nm to 998 nm,
whereas micelles made of PEG2k-GPLG↓IAGQ-TAT-PEG1k-PE slightly increased in size from 93
nm to 102 nm. In addition, the non-aggregating micelles did not show a significant increase in
drug release (about 50% release with and without collagenase), whereas the aggregated micelles
showed significant increase in paclitaxel release (80% in comparison to 50% without collagenase).
In the first micelle, the cleavage of PEG2k -GPLG exposes the cell penetrating TAT peptide on the
surface while maintaining the structural integrity of the micelle due to the additional PEG1k group
in the remaining building block, IAGQ-TAT-PEG1k-PE. In the second micelle, only IAGQ-TATPE is left, which disrupts the amphiphilic balance and the structural integrity of the micelle,
resulting in increased release of paclitaxel and aggregation of the post-enzymatic product. The
TAT activated and paclitaxel-loaded micelles were able to penetrate and reduce the size of
NCI/ADR-RES (ovarian tumor) spheroids significantly more than the aggregating counter micelle
and were retained longer in tumors of mice in vivo.
Ge et al. developed block-co-polymer with poly-D, L lactide and PEG linked by MMP-2
cleavable linker (PEG113-GPLG↓VRGDG-PDLLA100) that can encapsulate paclitaxel and form 62
nm spherical micelles. When the particles were incubated with 1 µg/ml of MMP-2, 80% of PEG113
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was cleaved in 25 hours observed by HPLC. Although the PEG113 layer was removed, the size of
the particle remained the same at 65 nm. In addition, the MMP-2 cleavage of PEG did not trigger
release of paclitaxel. At 72 hours, 80% of paclitaxel was released from the micelle with and without
incubation with MMP-2. When the PEG113 is cleaved from this micelle, the PDLA100 core remains
conjugated to VRGDG which is surprisingly sufficiently hydrophilic to keep the particles from
aggregating. The drugs remain within the core of the micelle and are unaffected by the MMP-2
triggered cleavage of PEG113. The paclitaxel-loaded MMP-activated polymer micelle was more
cytotoxic to 4T1 cells (breast tumor) in vitro and was able to inhibit tumor growth significantly in
H22 tumor (hepatic carcinoma) bearing mice in comparison to free paclitaxel in vivo. The two
examples by Ge and Zhu, and one more in Table 4, show that de-PEGylation of these micelles
does not cause morphology change in the nanoparticle nor induce drug release and the anti-cancer
efficacy of the treatments are increased.

2.5. Summary and future directions
In this chapter, we analyzed MMP-responsive nanomaterials and drew conclusions on
guiding principles to design nanomaterials with specificity and functionality. First, the hydrolysis
rate of MMP-cleavable peptide can be tuned by modifying the peptide substrate or the morphology
and electrostatic charge of the nanomaterial that hosts it. Specificity towards a specific MMP can
also be tuned by these methods. Second, the rate of payload release can be controlled by choosing
the mode of response in the nanomaterial after MMP action. In general, the rate of MMP-induced
payload release is delayed from the nanomaterial response. Third, the mode of response can have
different advantages in the biological context. Size shrinking particles can penetrate deeper into
solid tumors and increase uptake intracellularly, cytotoxic nanofibers can achieve highly selective
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toxicity in vitro and enhance the efficacy of drugs in vivo, and activated nanoparticles can reveal
targeting ligands without inducing payload release or morphological change. The two examples of
aggregating particles did not always increase the efficacy of the drugs, however, the overall
systematic toxicity was lowered in vivo, and increased efficacy was observed in drug-resistant cell
lines. Currently, the efficacy of anti-cancer treatments is measured by the ability to kill cells and
reduce tumor size. However, as observed in this chapter, MMP-responsive systems do not always
increase the toxicity nor tumor reducing ability of the payloads. Instead, the system achieves more
selective and targeted therapy which could potentially reduce adverse side effects and transform
current chemotherapy into safer treatment options.
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Chapter 3
Customizing Morphology, Size, and Response Kinetics of Matrix Metalloproteinase-Responsive
Nanostructures by Systematic Peptide Design

Summary
Over-expression and activation of matrix metalloproteinase-9 (MMP-9) is associated with
multiple diseases, and can serve as a stimulus to activate nanomaterials for sensing and controlled
release. In order to achieve autonomous therapeutics with improved space-time targeting
capabilities, several features need to be considered beyond the introduction of an enzymecleavable linker into a nanostructure. We introduce guiding principles for a customizable platform
using supramolecular peptide nanostructures with three modular components to achieve tunable
kinetics and morphology changes upon MMP-9 exposure. This approach enables: (1) fine-tuning
of kinetics through introduction of ordered/disordered structures, (2) a 12-fold variation in
hydrolysis rates achieved by electrostatic (mis) matching of particle and enzyme charge, and (3)
selection of enzymatic reaction products that are either cell-killing nanofibers or that disintegrate.
These guiding principles, which can be rationalized and involve exchange of just a few amino
acids, enable systematic customization of enzyme-responsive peptide nanostructures for general
use in performance optimization of enzyme-responsive materials.
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3.1. Introduction
Nanomaterials impact biomedicine by taking advantage of their inherent chemical and
physical properties to achieve increased circulation lifetime and selective bio-distribution in vivo,
and dictate cellular uptake mechanisms,1 all of which cannot be attained by molecular drugs alone.
Another beneficial feature of nanomaterials is the ability to incorporate stimuli-responsive
functionalities to enhance selectivity in targeting diseased cells, and manipulate drug release
profiles.2–5 In particular, an inherent biological stimulus such as (over-) expression of enzymes,
can serve as a marker for diseased cells, as well as a trigger to facilitate desired changes in the
nanostructure.6 Understanding the relationship between properties of nanomaterials, such as size,
shape, and charge, with their bio-distribution or cellular uptake patterns have allowed researchers
to develop refined systems to target specific organs and cells. For example, Discher et al. described
that the increase in length of flexible filomicelles up to 8 m increased the circulation lifetime in
vivo in mice, in comparison to shorter filomicelles and spherical vesicles.7 Likewise, a thorough
investigation is necessary in order to develop design rules for nanomaterials that can engage with
the enzymatic stimuli with varying degrees of affinity in order to predetermine response kinetics
for the desired enzyme-responsive action (i.e. disassembly, morphology switch, etc.).6
For instance, an over-expression and activation of matrix metalloproteinase-9 (MMP-9),
an enzyme that is crucial to normal behavior of cells such as degradation of extracellular matrix,8
is associated with multiple diseases including cancer metastasis,9 cardiovascular diseases,10
arthritis,11 etc. Since the introduction of polymeric MMP-responsive materials by Hubbell et
al.,12,13 there have been numerous strategies to exploit this highly disease-relevant enzyme for biomedical applications.14–21 One of the challenges in designing MMP-9 responsive nanomaterials is
optimizing a cleavable segment that meets the enzyme specificity,22 and is concurrently compatible
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with the nanoparticle system. Another, largely overlooked but important aspect of particle design
is regulating the susceptibility of the nanoparticle to the enzyme stimuli through the manipulation
of electrostatic properties of nanoparticles to attract or repel enzymes of opposite or same charge,23
and to control the degree of supramolecular organization of the nanoparticle to increase or limit
enzyme access to the particle, and ultimately influence the observed reaction and response
kinetics.24
A further design aspect is the morphology of the particle pre- and post-cleavage; there is
increasing evidence that enzymatically triggered formation of nanofibers on tumor cells can cause
cytotoxic effects,14,25 and Xu et al. have extensively studied this mechanism to overcome drugresistance in cancer cells,26,27 while disintegrating particles may be beneficial for controlled drug
release.19,20 The anti-cancer activity of the nanofibers depends on the kinetics of fiber formation
which in turn depend on the interaction between the enzyme and the precursor, as well as the selfassembling ability of the post-enzymatic product.28 By employing these strategies, the response
behavior of the enzyme-responsive nanomaterials can be optimized to achieve selective and
controlled rates of drug release, and to introduce additional therapeutic functionalities.
Thus, by using rational design of peptide sequences, we present here a modular platform
to customize surface charge, supramolecular organization, and enzyme specificity of peptide
nanostructures. We demonstrate the significance of these properties in showing that simple, few
amino acid replacements can systematically control enzyme engagement and susceptibility to the
enzymatic action. This further dictates the response kinetics and the action of the nanostructures
(degradation or -sheet formation) to ultimately influence cells’ fate.
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3.2. Rational design of peptide sequences
For this study, we designed self-assembling peptide amphiphiles29 that form stable
nanostructures under physiological conditions, and undergo morphological change or degradation
upon MMP-9 hydrolysis of the peptides. This study is based on our previous work which
demonstrated that peptide micelles can encapsulate doxorubicin and transform into fibrous drug
depots upon MMP-9 action.15,30 Thus, we created a modular system in which the peptide sequences
contain three segments: (1) cationic or anionic hydrophilic segment to modulate enzyme
engagement, (2) MMP-9 cleavable segment with ordered or disordered regions to influence
enzyme kinetics and predetermine self-assembly or dis-assembly of post-cleavage product and,
and (3) hydrophobic segment to drive self-assembly of precursor and of post-enzymatic selfassembling product (with potential to bind hydrophobic drugs)15 (Figure 1).
To demonstrate the ability to electrostatically recruit MMP-9 (pI = 5.7, net negative charge
in physiological pH)31 to the peptide particles, we designed a hydrophilic segment in the peptide
amphiphiles with cationic or anionic C termini. Each peptide was given a positive (1-3 AK/PK)
or negative (1-3 AD/PD) charge using two lysine or two aspartic acid residues, thus creating 12
sequences (Table 1). In addition, these surface charges increase solubility of the peptide
nanostructures and can be customized to potentially influence cellular uptake and bio-distribution.
To achieve MMP-9 specificity, and to program the distinct morphologies of the peptide
nanostructures and the resulting enzymatic products, we designed the cleavable segment based on
data from the MEROPS database,32 which suggests PX1GLX2G, where  represents the scissile
bond, and X1 and X2 represent positions where there are no significant preferences for a single
amino acid. The amino acid positions are designated starting from the scissile bond (red dash line
in Table 1) and are labeled P1 through P6 towards the N terminal, and P1’ and P5’ towards the C
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terminal. Peptides 1-3 PK/PD contain Pro in P3 which is prevalent in substrates of most MMPs,22
however, Pro is known to disrupt assembly of secondary structures like -helices and -sheets in
proteins.33 Therefore, in order to promote fiber formation of the post-cleavage enzymatic products,
we substituted Pro for Ala in P3 in 1-3 AK/AD which is also found in natural substrates of MMP9.34 In addition, we varied P2 with small aliphatic residues to observe differences in enzyme
specificity, and inserted Gly in P4 to change the self-assembling behavior of peptides and observe
the consequent changes in enzyme kinetics.

Table 3.1. Single letter code of 12 peptides before MMP-hydrolysis where the red dash line
indicates expected cleavage site, and the post-enzymatic products (P5-P1 or P6-P1).
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Figure 3.1. Cartoon of sequence dependent peptide nanostructures. (A) Chemical structure and
(B) cartoon of self-assembling peptide amphiphiles that respond to MMP-9 action. Positive (blue)
or negative (red) charges on the nanoparticle electrostatically recruit or repel MMP-9 to influence
enzyme kinetics. Self-assembling (purple) and MMP-9 cleavable segments (gray and/or orange)
dictate the susceptibility of the nanostructures to MMP-9 hydrolysis by forming
ordered/disordered structures, and control the fiber formation or disassembly of the post-enzymatic
products. Red dash line indicates the scissile bond.

Lastly, to introduce the hydrophobic segment of our amphiphilic peptides, we used the
well-known self-assembling sequence diphenylalanine35,36 on the first two positions of the N
termini to drive self-assembly of nanostructures prior to enzyme action via hydrophobic and
aromatic interactions, and to form nanofibers in a subset of sequences after enzyme action (1-3
AK/AD). These 12 sequences represent a modular design in which the rate and morphology of the
enzymatic response can be customized for desired applications.
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3.3. Characterization of the pre-enzymatic peptide nanostructures
The 12 pre-enzymatic (1-3 AK/AD and 1-3 PK/PD) and 6 post-enzymatic (1-3 A and 1-3
P) peptide sequences were synthesized using Fmoc-based solid phase peptide synthesis (SPPS),
purified on a preparatory high-performance liquid chromatography (HPLC) using C18 column,
lyophilized in water, and identified by high resolution liquid chromatography-mass spectrometry
(HRMS) and 1H nuclear magnetic resonance (NMR) spectroscopy. The self-assembly of peptide
nanostructures was investigated using CAC, FTIR, and ζ-potential, and finally the morphology of
the nanostructures was imaged using AFM and TEM.
The CAC values for the 12 precursor peptides were determined using pyrene as a
solvachromatic fluorophore in PBS (pH 7.4) and are listed in Table 2. In general, the cationic
peptides had the lowest CAC of 0.3 mM and 0.4 mM for 1-2 PK and 1-2 AK, respectively, except
for 3 PK and 3 AK which aggregated at 0.7 mM and 0.8 mM, respectively. While the CAC of PK
peptides were lower than its analogous AK peptides, no clear trend was observed for the anionic
peptides. On the contrary to the cationic peptides, which had the highest CAC for 3 AK and 3 PK,
the counter peptides 3 AD and 3 PD had the lowest CAC of 0.5 mM among the anionic peptides.
According to clogP values predicted using Chemdraw, the cationic peptides are more hydrophobic
(higher clogP) than the anionic peptides and have overall lower CAC than anionic peptides. In
addition, the cationic peptides show a positive correlation of larger CAC values for lower cLogP
values (more hydrophilic peptides) (Figure 2). However, for the anionic peptides larger CAC
values were observed for smaller cLogP values (more hydrophobic peptides) with exception of 1
PD.

57

Table 3.2. Critical aggregation concentrations of peptides determined using pyrene (Figure S2526) and log of partition coefficient (coctanol/cwater) as predicted by Chemdraw.

Figure 3.2. CAC vs. clogP to compare the trends in hydrophobicity and aggregation propensity.
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The ζ-potentials of the peptide assemblies confirmed the presence of the expected positive
or negative charges and the average ζ-potential values for the 12 precursor peptide nanostructures
are listed in Table 3. Higher zeta potentials were observed for the anionic peptides which have
negatively charged Asp residues on the free carboxyl termini of the peptides, in comparison to the
cationic peptides in which the positive charge of Lys residues is negated by the free C termini. We
note that measurements were made at high concentrations (5 mM) due to the limited light
scattering properties of the peptide particles that may have contributed to aggregation which results
in overall lower zeta potential values.
Table 3.3. ζ-potentials of 5 mM peptides in 2% PBS (pH 7.4) at 25C (Figure S27-32).

Analysis of Fourier-transform infrared spectroscopy (FTIR) spectra reveal that the selfassembly of most of the peptide sequences are not majorly driven by highly ordered hydrogen
bonding of the peptide backbones. Instead, the major peaks in the amide I region absorb between
1640-1650 cm-1, indicative of disordered hydrogen bonds (shaded green in Figure 3C-D).37 Thus,
the major contribution in the self-assembly of 1-3 PK/PD and 2-3 AK/AD is driven by the
formation of diphenylalanine hydrophobic core solubilized by the hydrophilic lysine or aspartic
acid tail.38
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Figure 3.3. AFM images and FTIR spectra of self-assembled peptide nanostructures. A-B) 1
AK/AD form large fibers organized in anti-parallel -sheet arrangement, 2-3 AK/AD and 1
PK/PD form elongated worm-like micelles, and 2-3 PK/PD form spherical micelles. Scale bar
500 nm. Additional AFM images can be found in Figure S33-34. C-D) FTIR spectra of the peptides
in amide I region. Red shade highlights the carboxylate groups (1580-1590 cm-1) which can red
shift to lower wavenumber (1541 cm-1 for 1 AD) upon cation complexation,39 blue shade highlights
parallel -sheet (near 1620 cm-1) and anti-parallel -sheet (additional peak at1688 cm-1) hydrogen
bonding of the peptide backbones, and the green shade highlights disordered hydrogen bonds
(1640-1650 cm-1). Peaks are listed in Table S1.
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Atomic force microscopy (AFM) images show that AK/AD sequences form onedimensional nanostructures and PK/PD sequences form spherical nanostructures with the
exception of 1 PK/PD (Figure 3A-B). Analysis of Fourier-transform infrared spectroscopy (FTIR)
spectra reveals that the self-assembly of most of the peptide sequences are not majorly driven by
highly ordered hydrogen bonding of the peptide backbones. Instead, the major peaks in the amide
I region absorb between 1640-1650 cm-1, indicative of disordered hydrogen bonds (shaded green
in Figure 3C-D).37 Thus, the major contribution in the formation of these spherical micelles (2-3
PK/PD) or worm-like micelles (1 PK/PD and 2-3 AK/AD) are driven by the formation of
diphenylalanine hydrophobic core solubilized by the hydrophilic lysine or aspartic acid tail. 38 In
contrast, 1 AK/AD show prominent characteristics of anti-parallel -sheet arrangement of the
peptide backbone which absorbs at 1620 and 1687 cm-1 for 1 AK and at 1623 and 1696 cm-1 for 1
AD (shaded blue in Figure 3C-D). In addition, the carboxylate peak, which absorbs in 1580-1590
cm-1 (shaded red in Figure 3C-D), is red shifted to 1541 cm-1 in 1 AD. This is indicative of cation
complexation which suggests intermolecular salt bridge formation between the C and N terminal
(or aspartic acid residues next to the C terminal) that contributes to the long-range order of the
peptide assembly.39 We speculate that these highly ordered nanofibers are caused by the assembly
of linear and rigid backbone of 1 AK/AD in P6-P1 (FFALG), and this is clearly evident in 1 PK/PD
in which a single amino acid substitution of Ala to Pro in P3 (FFPLG) creates a kink in the peptide
backbone and significantly disrupts the anti-parallel -sheet formation. Furthermore, the addition
of Gly in P4 (FFGAX1G) in 2-3 AK/AD adds flexibility to the peptide backbone40 which hinders
long range order of the peptide assembly and thus forms smaller nanofibers.
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3.4. Controlling enzyme kinetics
Next, we measured the rate of MMP-9 cleavage of the 12 peptides. Lyophilized peptides
were dissolved in phosphate-buffered saline (PBS) supplemented with 1 mM CaCl2 and 55 M
ZnCl2 to be compatible with MMP-9 (a metalloproteinase with zinc and calcium dependent
catalytic domain), the pH adjusted to 7.4, and sonicated for 10 mins to achieve 1 mM of peptide
solutions. 100 ng/mL MMP-9 was incubated with peptides at 37C and the reaction was monitored
up to 96 h using LC-MS to identify and quantify the enzymatic products by calculating the area of
the product peak over the initial peptide peak (Figure S35-46).

3.4.1. Electrostatic recruitment or repulsion of MMP-9
Comparing the P1P1’ enzymatic products, the cationic peptides (Figure 4A) were
preferentially cleaved by (anionic) MMP-9. For example, 2 PK had a 12-fold higher conversion
in comparison to 2 PD (Figure 4B). This stark difference resulting from preferential hydrolysis of
nanostructures by oppositely charged enzymes has also been observed by Wooley et al.24 using
polymeric micelles.
Interestingly, the major cleavage site for the cationic peptides was between GL in P1P1’
as anticipated, whereas the major cleavage site for the anionic peptides was between FF in P6P5
with inconsistent results between two separate trials (Table S2). It has been reported that MMP-9
cleavage site in peptides of similar length can shift to P2P1 or P1’P2’,41 but this drastic shift to
P6P5 suggests that the anionic peptides do not meet MMP-9 specificity. By electrostatic (mis)
matching, we are able to recruit or repel MMP-9 to trigger the desired response in the nanomaterial.
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Figure 3.4. 1 mM of (A) 1-3 AK/PK and (B) 1-3 AD/PD incubated with 100 ng/mL of MMP-9
at 37C. Peptides with Pro in P3 are marked grey, and Ala with orange. Average % conversion of
peptides to the post-enzymatic products (P1P1’) from two separate trials. 1-3 PK showed the
highest conversion and further degradation of the post-enzymatic product was observed for 2 PK
(blue dash line). Over 50% of 2 AK was cleaved, while less than 10% of 3 AK and 1-2 PD was
converted, and the rest were not responsive to MMP-9.

3.4.2. Increasing or limiting accessibility to enzymatic hydrolysis
In addition to the dramatically different conversion rates (and cleavage sites) resulting from
electrostatic interactions, we can further fine-tune the rate of enzymatic hydrolysis by achieving
enzyme specificity and by controlling the degree of order in the supramolecular peptide
nanostructures. Of the cationic peptides, sequences with Pro in P3 (1-3 PK) were almost
completely digested by MMP-9 within 96 h. In particular, 1 PK, which forms the smallest micelles
of the three, was completely converted to the enzymatic product, FFPLG, in 48 h, and continued
to be further hydrolyzed between FF (dash blue line in Figure 4A). This demonstrates the
biodegradability of peptide nanoparticles, which may be useful for applications where (di)
phenylalanine generated amyloid-like toxic fibrils are of concern.42 Overall, 1-3 PK were cleaved
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to completion at a similar rate due to the preferred Pro residue in P 3, and the subtle differences in
the peptide sequences did not affect the enzymatic hydrolysis rates.
In the case of 1-3 AK, significant differences were observed due to the degree of
supramolecular organization of the nanostructures. 3 AK, which has the highest CAC value of
0.8mM, had a low conversion (below 10% by 96 h), whereas, 2 AK with a lower CAC value of
0.4 mM had the highest conversion (up to 60% by 96 h), and no cleavage was observed for 1 AK
(CAC value 0.4 mM). These data suggest that the kinetics of the enzyme hydrolysis are determined
by the supramolecular order of the peptide assemblies rather than the hydrolysis of unassembled
peptide monomers. The slight difference of introducing a glycine residue in the sequences of 2 AK
and 1 AK (between diphenylalanine and alanine) contributes to a major change in the morphology
of the two nanostructures. 2 AK, which has a more flexible peptide backbone due to the insertion
of Gly residue in P4, forms disordered hydrogen bonds (Figure 3C) that leads to the formation of
smaller fibrils (Figure 3A and Figure S33) and is susceptible to MMP-9 hydrolysis. However,
without the Gly residue, the rigid peptide backbone of 1 AK in P6-P1 arranges in an anti-parallel
-sheet configuration (Figure 3C) and form fibers that are microns in length (Figure 3A and Figure
S33). These highly organized fibers are less susceptible to enzyme degradation, especially for the
endopeptidase MMP-9, which has been observed to bind to type I fibril collagen, a large extra
cellular matrix component, but cannot digest it until it is in the denatured, gelatin form.43
Concluding from this set of 12 peptides, it is clear that we can dramatically control the rate and
specificity of MMP-9 hydrolysis through systematic exchange of amino acids.
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3.5. Characterization of post-enzymatic peptide nanostructures
The hydrophobic N terminal fragments of the resulting enzymatic products (herein referred
as 1-3 A/P) by SPPS and characterized using HRMS, 1H NMR, AFM, and FTIR. Controlling the
morphology of the post-enzymatic products is important in designing MMP-responsive
nanomaterials. For instance, enzyme-triggered fibers which form on or near the cell surface of
cancer cells that produce the enzyme stimuli are known to be cytotoxic to the cells, 44 and
disassembling nanocarriers can be used for burst release of payloads. Distinct differences can be
observed by peptides with Ala in P3 (1-3 A) which formed ordered structures, and peptides with
Pro in P3 (1-3 P) which was expected not to self-assemble due to the Pro disrupting formation of
ordered hydrogen bonds. FTIR spectra of the non-assembling peptides (Figure 5B gray lines) show
absorptions at 1641, 1643 and 1653 cm-1 for 1 P, 2 P and 3 P, respectively, which is observed for
amides of peptide backbones with disordered hydrogen bonds. A mixture of parallel -sheet (1628
cm-1) and disordered (1643 cm-1) hydrogen bonds were observed for 2 A. In contrast, 1 A absorbs
at 1627 and 1687 cm-1, and 3 A absorbs at 1624 and 1688 cm-1, which are distinct characteristic
peaks of anti-parallel -sheet hydrogen bonds (Figure 5B orange lines). AFM images (Figure 5A)
show that 1-3 P form random aggregates. In comparison, 1-3 A form fibers.
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Figure 3.5. AFM and FTIR of synthesized post-enzymatic products. (A) AFM image of 1-3 A
(top panel, left to right) and 1-3 P (bottom panel, left to right). Scale bar 500 nm. (B) FTIR spectra
of 1-3 A in orange and 1-3 P in gray lines.

3.5.1. Enzymatically formed fibers have higher order assembly
The morphology of the enzymatic products of 2 AK and 2 PK incubated with MMP-9 was
monitored over time by FTIR and AFM. In addition to identifying and quantifying the postenzymatic products of peptides after incubation with MMP-9 (Figure 4), the morphology of the
reaction product was also monitored over time for 2 AK and 2 PK by FTIR and AFM. Figure 6B
shows that the disordered region of 2 AK (black line) disappears by 24 h and a sharp peak is
observed in the 1620 cm-1 region indicative of ordered β-sheet hydrogen bonds (purple line). By
48 h, an additional peak at 1680 cm-1 region can be observed which indicates the peptides are
arranged in an anti-parallel β-sheet manner (pink line). In comparison, the synthesized 2 A,
although identical in chemical composition (FFGALG), has a completely different absorbance and
less order than the MMP-9 induced assembly. The AFM image of 2 AK after 24 h incubation with
MMP-9 shows that enzymatically formed 2 A also forms fibers (Figure 5A). On the other hand,
66

the FTIR of 2 PK does not change after incubation with MMP-9 or in comparison to the
synthesized 2 P (Figure 6D). However, the AFM images of 2 PK prior to incubation with MMP9 show formation of uniformly spherical micelles about 50 nm in diameter (Figure 3A). The
synthesized 2 P and the enzymatically formed 2 P both show small random aggregates, which
confirms the lack of ordered hydrogen bond absorbance by FTIR.

Figure 3.6. AFM images of 2 AK at 24hr (A) and 2 PK at 24hr (B), scale bar 500nm. (C) FTIR
absorbance of 2 AK: 0 h, 24 h, 48h (0%, 24%, and 24% enzymatic products, respectively) and 2
A for comparison. (D) FTIR absorbance of 2 PK: 0 h, 24 h, 48h (0%, 86%, and 91% enzymatic
products, respectively) and 2 P for comparison.

3.6. Biocompatibility of peptide nanostructures in vitro
Moving forward, we chose to test the biocompatibility of the two peptides that were active
against MMP-9, 2 AK and 3 AK, and their Pro analogous peptides 2 PK and 3 PK. We chose a
human clear cell renal cell carcinoma line, Caki-1, because tissues from patients with this type of
kidney cancer show significantly higher expression of MMP-9 mRNA, with increasingly higher
expression in advanced tumor stages.45 As a control, we chose a non-cancerous human lung
67

fibroblast cell line, IMR90, which was reported to have negligible expression of MMP-9 mRNA.46
1 mM of the peptides were incubated with Caki-1 and IMR90 cells at 37C for 72hrs and the cell
viability was determined using the Presto Blue assay (Figure 3.7. A-B). The peptides are non-toxic
to both cell lines with cell viabilities over 90%, except for 3 AK which forms -sheet fiber postcleavage and decreased the cell viability of Caki-1 cells to 66%, despite the observed low
conversion (Figure 4A).

Figure 3.7. Biocompatibility of peptide nanostructures. Cell viability of human renal cancer cell
line, Caki-1, with high expression of MMP-9 (A), and non-cancerous human fibroblast, IMR90,
with normal expression of the enzyme (B), incubated with 1 mM peptides for 72 hrs. The peptides
are non-toxic to both cell lines, except for 3 AK which decreased the cell viability of Caki-1 to
66%. (C) FTIR spectra of the post-cleavage peptides show that only 3 A forms anti-parallel sheet peptide fibers which causes the cytotoxic effects in Caki-1 only. (D) TEM images of 3 AK
and 2 PK show formation of worm-like and spherical micelles, respectively, and the post-
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enzymatic products, 3 A and 2 P which form rigid fibers or random aggregates, respectively. Scale
bar 100nm.

3.6.1. Nanofibers induce selective toxicity in cancer cells
In order to understand the effects of the post-cleavage products in vitro, we examined the
hydrophobic N terminal fragments of the resulting enzymatic products characterized in section
4.5. In comparison to 2 P and 3 P, which form random aggregates, 2 A formed short fibers and 3
A formed large fiber bundles (Figure 5A). TEM images (Figure 7D) show that the precursor 2 PK
forms spherical particles which, when converted to 2 P, disassemble and remain as random
aggregates. In comparison, precursor 3 AK forms flexible fibers and the post-enzymatic product,
3 A, forms ordered rigid -sheet fibers. Enzyme-triggered fibers which form on or near the cell
surface of cancer cells that produce the enzyme stimuli are known to be cytotoxic to the cells. 44
Likewise, the observed decrease in viability of Caki-1 cells treated with 3 AK is most likely due
to the formation of toxic anti-parallel -sheet nanofibers (3 A) that are selectively triggered to form
by the overexpressed MMP-9 in the diseased cells.44 This effect is not observed in the control cell
line, IMR90, where overexpression of MMP-9 is not expected.

3.7. Conclusion
In conclusion, we have created a modular system of self-assembling peptide nanostructures
to customize surface charge and supramolecular order to control enzyme kinetics and response
action. These peptide nanostructures are bio-degradable and non-toxic, and after enzyme action,
the non-assembling products remain non-toxic while the -sheet nanofiber forming products can
selectively kill cancer cells. The kinetics of nanoparticles is important in biomedical applications
in which the rate of enzyme responsiveness should be regulated (i.e. predetermined drug release
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profile, degradation rate of hydrogels, etc.). In addition, the morphology of the nanoparticles
should be logically designed to achieve optimal function of the precursors (i.e. manipulation of
cellular uptake, bio-distribution, etc.) and of the post-enzymatic product (i.e. biodegradability or
therapeutic nanofiber/drug depots, etc.).
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3.9. Methods
Solid Phase Peptide Synthesis (SPPS). Fluorenylmethyloxycarbonyl (Fmoc)-protected amino
acids and pre-loaded Wang resins were purchased from Bachem. Peptides were synthesized on
CEM Liberty Blue microwave assisted solid phase peptide synthesizer using ~1:5 resin to amino
acid

ratio

and

excess

of

diisopropylcarbodiimide

(DIC),

Oxyma

(Ethyl(hydroxyimino)cyanoacetate), and 20% piperidine in dimethylformamide (DMF). The
complete peptide-loaded resins were washed three times in dichloromethane, followed by three
washes in diethyl ether on a filtration column. The peptides were cleaved from the resins and side
chain protecting groups were removed by reacting with TFA cocktail (95% trifluoroacetic acid,
2.5% triisopropyl silane, and 2.5% water) for 2 h. The cleaved peptides were recovered by
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removing TFA cocktail, followed by precipitation in cold diethyl ether. Peptides were washed three
times in cold diethyl ether, using centrifugation to collect the precipitated crude peptide.
Preparatory High-Performance Liquid Chromatography (HPLC). Crude peptides were
dissolved in 50% acetonitrile in water containing 0.1% TFA and purified through a preparatory C18
column on the Thermo Scientific Dionex Ultimate 3000. Acetonitrile was removed from the
collected fragments on a rotary evaporator before lyophilization in MQ water or 10 mM HCl to
remove residual TFA salts.
TFA removal. Removing residual TFA salts is crucial for investigation of self-assembled peptide
nanostructures. Chapter 4 will go over the issues that arise when residual TFA salts are ignored
and a detailed procedure on how to remove them will be provided.
High Resolution Mass Spectrometry (HRMS). HRMS data were obtained on an Agilent 6550
QToF, with a dual sprayer ESI source, coupled to an Agilent 1290 Infinity LC system. Samples
were analyzed by FIA (flow injection analysis) using a mobile phase of 50% acetonitrile in water
(0.1% formic acid) with a flow rate of 0.4 mL/min.
1H

Nuclear Magnetic Resonance (NMR) Spectroscopy. Spectra were recorded on a Bruker

AV400 at 400 MHz. Chemical shifts (δ) are given in ppm using D2O as solvent.
Critical Aggregation Concentration (CAC). The critical aggregation concentrations of the
precursor peptides were determined using pyrene as a fluorescent probe (Figure 2 and Table 2).
Briefly, 1 mM of peptides were prepared in PBS and the pH was adjusted to 7.4 using 0.5 M NaOH
or 0.5 M HCl prior to serial dilution in PBS with thorough vortexing. Peptide solutions were
incubated at 50C for 15 minutes, then 2 L of stock pyrene solution (100 M in methanol) was
added to 100 L of each peptide solution, gently mixed, and incubated for 5 minutes at 50C, then
finally cooled down to room temperature to co-assemble the peptides with pyrene molecules.
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Pyrene emission spectra were measured from 350-450 nm (ex = 310 nm) in a micro fluorescence
cuvette (3 mm path length) on Jasco FP-8500 Spectrofluorometer (measurement parameter: 20 nm
excitation and 1nm emission bandwidth, 0.2 sec response, medium sensitivity, 0.2 cm -1 data
interval, at 200 nm/min). The CAC was determined by plotting the ratio between intensities of the
3rd to 1st peak of the pyrene emission spectra (Figure S25-26). Increasing peptide concentrations
were measured in 0.1 mM increments until the slope of the plot had changed, and simultaneously
the 3rd peak shifted from 382.4 nm to 384.4 nm and the 1st peak shifted from 371.8 nm to 373.4
nm.
ζ-potential. Measurements were made using an Anton Paar Litesizer 500 Particle Analyzer. 5 mM
of peptide samples were prepared in 2% PBS and the pH was adjusted to 7.4 using dilute NaOH
and HCl. 50 µL of samples were pipetted into Univette low volume cuvette and three series of
measurements were taken at 25C using Smoluchowski approximation.
Fourier Transform Infrared Spectroscopy (FTIR). Absorbance spectra were taken from 4000
cm-1 to 800 cm-1 with 64 scans at 4 cm-1 resolution on the Bruker Vertex 70 spectrometer. 20 mM
peptide solutions were prepared in deuterated phosphate buffer (pH = 8), pH was adjusted to 7.4
using 0.5 M NaOH or 0.5 M HCl and sonicated for 10 min. 5 L of sample solutions were drop
casted between two CaF2 cells with PTFE spacers (12 m thickness x 13 mm diameter). For
analysis, deuterated phosphate buffer absorbance spectrum was subtracted from the sample
absorbance and spectra were normalized from 1560 to 1655 cm-1.
Atomic Force Microscopy (AFM). Images were taken on Bruker Dimension FastScan using
FASTSCAN-B tip on fast scan mode. 1 mM of peptide solution was prepared in phosphate buffer
(pH 7.4), sonicated for 10 min and drop casted on freshly cleaved mica and allowed to dry for 48
h before imaging.
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Transmission Electron Microscopy (TEM). TEM images were taken on FEI Titan Halo 80-300
microscope. 1 mM of peptide solution was prepared in 10 mM phosphate buffer (pH 7.4) sonicated
for 10 min and 5 L of the solution was drop casted on a carbon film grid (400 mesh, copper) and
dried completely. To the dry grid, 5 L of MilliQ water was drop casted and quickly blotted to
wash away the phosphate salts and dried completely. Finally, 5 L of methylamine vanadate based
negative stain (NanoVan® by Nanoprobes) was drop casted, blotted away, and dried completely.
Cell lines. Human clear cell renal cell carcinoma line Caki-1 was newly obtained for these studies
from the American Type Culture Collection (ATCC) (Manassas, Virginia, USA) and cultured in
Roswell Park Memorial Institute (RPMI-1640) (Mediatech Inc., Manassas, VA) media containing
10% Fetal Bovine Serum, certified, heat inactivated, US origin (FBS) (Gibco, Life Technologies,
US), 1% Minimum Essential Media (MEM) nonessential amino acids (NEAA, Mediatech) and
1% penicillin–streptomycin (PenStrep, Mediatech). IMR90 (human fetal lung fibroblast) cells
were purchased from ATCC (Manassas, Virginia, USA) and maintained in Dulbecco's modified
Eagle's medium (DMEM) (Mediatech) supplemented with 10% FBS, 1% NEAA and 1% Penicillin
Streptomycin.
Cell viability assay. Human fetal lung fibroblast (IMR90) and human clear cell renal cell
carcinoma cells (Caki-1) were seeded in 96-well flat bottom microplate (BioLite Microwell Plate,
Fisher Scientific, Waltham, MA). For IMR90 we used 6.0 X 103 cell per well and for Caki-1 we
used 5.6 X 103 cells per well in 90μL of complete phenol red free cell culture media. The cells
were allowed to grow for 24hours at 37°C and 5% CO2 in a humidified incubator. 10mM peptide
solutions were prepared in phosphate buffer saline, pH adjusted to 7.4 using NaOH or HCl and
sonicated for 10minutes. Then 10μL of each sample was added into wells containing 90μL of
media (in triplicate). Following the administration of the peptides, cells were incubated for 72
73

hours at 37°C under 5% CO2. After each period of incubation, Presto Blue (Life Technologies,
Carlsbad, CA) was used as an indicator of cellular toxicity; 11μL of presto blue was added to each
well and incubated for 1 hours at 37°C under 5% CO2. The 96-wells plate was then analyzed using
a multi-mode plate-reader BioTek Microplate Reader (BioTek U.S., Winooski, VT) at 530nm and
590nm wavelength. The percentage of surviving cells was calculated as a normalized ratio of the
fluorescence intensity between cells treated with media and phosphate buffer saline alone.
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3.11. Supplementary Information

Figure S1. HR-MS spectra of peptides 1 AK/AD.
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Figure S2. HR-MS spectra of peptides 1 PK/PD.

Figure S3. HR-MS spectra of peptides 2 AK/AD.

Figure S4. HR-MS spectra of peptides 2 PK/PD.
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Figure S5. HR-MS spectra of peptides 3 AK/AD.

Figure S6. HR-MS spectra of peptides 3 PK/PD.
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Figure S7. HR-MS spectra of peptides 1 A/P.

Figure S8. HR-MS spectra of peptides 2 A/P.
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Figure S9. HR-MS spectra of peptides 3 A/P.

Figure S10. 1H NMR spectra of 1 AK.
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Figure S11. 1H NMR spectra of 1 AD.

Figure S12. 1H NMR spectra of 1 PK.
84

Figure S13. 1H NMR spectra of 1 PD.

Figure S14. 1H NMR spectra of 2 AK.
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Figure S15. 1H NMR spectra of 2 AD.

Figure S16. 1H NMR spectra of 2 PK.
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Figure S17. 1H NMR spectra of 2 PD.

Figure S18. 1H NMR spectra of 3 AK.
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Figure S19. 1H NMR spectra of 3 AD.

Figure S20. 1H NMR spectra of 3 PK.
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Figure S21. 1H NMR spectra of 3 PD.

Figure S23. 1H NMR spectra of 1 A.
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Figure S24. 1H NMR spectra of 1 P.

Figure S23. 1H NMR spectra of 2 A.
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Figure S24. 1H NMR spectra of 2 P.

Figure S23. 1H NMR spectra of 3 A.
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Figure S24. 1H NMR spectra of 3 P.

Figure S25. CAC of 1-3 AK and 1-3 PK.
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Figure S26. CAC of 1-3 AD and 1-3 PD.

Figure S27. Triplicate measurements of ζ-potentials of 1 AK/AD.
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Figure S28. Triplicate measurements of ζ-potentials of 1 PK/PD.

Figure S29. Triplicate measurements of ζ-potentials of 2 AK/AD.
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Figure S30. Triplicate measurements of ζ-potentials of 2 PK/PD.

Figure S31. Triplicate measurements of ζ-potentials of 3 AK/AD.
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Figure S32. Triplicate measurements of ζ-potentials of 3 PK/PD.
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Figure S33. AFM images of 1-3AK/PK. Scale bar 500 nm.

Figure S34. AFM images of 1-3AD/PD. Scale bar 500 nm.
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Table S1. FTIR absorbance of 1-3 AK/AD, 1-3 PK/PD, and 1-3 A/P in the amide I region.

Table S2. The enzymatic products were identified and quantified for two separate trials. Column
‘# K/D’ lists the MW of the 12 peptides and column ‘P6-P1’ lists the MW of the N termini portion
of the enzymatic product (and observed major products for the anionic peptides).

98

Figure S35. LCMS spectra of 1 AK in A) first and B) second separate trials.

Figure S36. LCMS spectra of 1 AD in A) first and B) second separate trials.

Figure S37. LCMS spectra of 1 PK in A) first and B) second separate trials.
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Figure S38. LCMS spectra of 1 PD in A) first and B) second separate trials.

Figure S39. LCMS spectra of 2 AK in A) first and B) second separate trials.

Figure S40. LCMS spectra of 2 AD in A) first and B) second separate trials.

100

Figure S41. LCMS spectra of 2 PK in A) first and B) second separate trials.

Figure S42. LCMS spectra of 2 PD in A) first and B) second separate trials.

Figure S43. LCMS spectra of 3 AK in A) first and B) second separate trials.
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Figure S44. LCMS spectra of 3 AD in A) first and B) second separate trials.

Figure S45. LCMS spectra of 3 PK in A) first and B) second separate trials.

Figure S46. LCMS spectra of 3 PD in A) first and B) second separate trials.
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Chapter 4
Residual Trifluoroacetate Salt Adducts Substantially Alters Self-Assembly of Peptide
Nanostructures

Summary
Trifluoroacetic acid (TFA), as the reagent of post synthesis cleavage of peptides from solid
phase, is commonly present in peptide products and is often ignored as an inert impurity. We
demonstrate that TFA forms stable adducts with amine groups of the peptides in water. These
adducts remain in place during aqueous solution and they can inhibit or otherwise influence the
self-assembly of peptide nanostructures by disrupting the intermolecular ionic and hydrogen
bonds. Using a peptide sequence which self-assembles to form nanostructures that are responsive
to MMP-9, we characterized and compared the self-assembly behavior of the peptide with different
concentrations of trifluoroacetate (TFAc) salts using
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F NMR, FTIR, AFM, TEM, critical

aggregation concentration assay, and ζ-potential. We show that TFAc dramatically alters the
morphology and properties of peptide nanostructures, which can lead to inconsistent
characterization and biological study results between batches of peptides containing different
concentrations TFA.
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4.1. Introduction
Self-assembling peptides are versatile in their chemical composition and provide an
excellent platform to design stable nanostructures such as micelles used in drug delivery or fibers
that form hydrogels for 3D cell culture.1 Using commercially available amino acids, any desired
peptide sequence can be readily synthesized due to the well-established solid phase peptide
synthesis (SPPS) procedure developed by Merrifield, who won the Nobel Prize in Chemistry in
1984.2 Most common methods of SPPS use trifluoroacetic acid (TFA) in the final step to remove
the peptide product from the solid resin and to cleave acid labile bonds such as the protecting
groups on the side chains of the amino acids (ex. lysine-Boc).3 However, the disadvantage of using
TFA is that it is difficult to remove due to the stability of the adducts formed. As a result, residual
trifluoroacetate (TFAc) often remains in the final peptide products, even in commercial
preparations that are sold as TFA free. In academic studies on peptide self-assembly, traces of TFA
are often ignored or they can lead to misinterpretation as part of the peptide characterization.
The impact of TFA is especially profound when the peptides are used to create
nanostructures by supramolecular self-assembly. It can change the molecular properties of the
peptide mainly by forming adducts with amine groups of the peptides that play key roles in
formation of hydrogen bonds or electrostatic interactions critical for self-assembly. Directly or
indirectly, the blocking of amine groups may impact the driving forces of peptide self-assembly
including electrostatic, hydrogen bonding, and cation-pi interactions. Specifically, the TFAc ion
can block positively charged functional groups from interacting with negatively charged residues,
as well as preventing formation of salt bridges between C and N termini that stabilize selfassembled peptides.
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Previously, our group has characterized Fmoc-FF peptide fibers co-assembled with FmocRGD that form hydrogels and can be used as 3D-scaffolds for anchorage-dependent cells.4 FmocFF self-assembles into β-sheets and showed a broad negative peak at 218 nm in CD and strong
absorbance at 1630 and 1690 cm-1 in FTIR spectra. Fmoc-RGD showed weak signals in both
analysis and a broad peak at 1655 cm-1 in FTIR, indicative of random coil arrangements. Thus, by
incorporating less or more % of Fmoc-RGD to Fmoc-FF fibers, the stiffness of the hydrogel was
controlled. Shortly after, Hamley et al. reported contradicting findings in which Fmoc-RGD could
self-assemble into β-sheets and form stable hydrogels by itself.5 However, as acknowledged by
the authors, this Fmoc-RGD contained high amounts of TFA, as clearly shown by the large 1673
cm-1 absorbance peak detected in FTIR. In contrast, the Fmoc-RGD used in our study did not
absorb at 1672 cm-1 in FTIR analysis. The authors compared the similar hydrogel dynamic elastic
shear moduli of their Fmoc-RGD hydrogel to their previously studied Fmoc-KLV(Boc) hydrogel,
emphasizing that this Lys residue is capped by a Boc protecting group, whereas Fmoc-RGD
contains uncapped Arg residue. In this case, the authors failed to realize that the high
concentrations of TFA acted like a protecting group on the Arg residue and formed hydrogels
similar to Fmoc-KLV(Boc), which resulted in completely different morphology from the
previously reported TFA free Fmoc-RGD.
Here we use a model peptide sequence with 3 amine groups, FFGALGLKGK, which was
previously described in Chapter 4 to form matrix metalloproteinase-9 (MMP-9) responsive
nanocarrier for biomedical applications. Full description of peptide FFGALGLKGK can be found
in Chapter 4 as peptide 2 AK. We report that residual TFAc salts in the peptide product
significantly changes the self-assembly behavior of peptides using 19F NMR, FTIR, AFM, TEM,
and show how this implication can contribute to false ζ-potential, critical aggregation
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concentration, and morphology. Lastly, we demonstrate how the changes in the nanostructure
properties can also affect biological studies, such as a delay in enzyme hydrolysis rates, and
ultimately cause irreproducibility in experiments.

4.2. Method development for washing TFA
A self-assembling peptide sequence, FFGALGLKGK, that was previously characterized
(Chapter 4) was used to demonstrate the significance of TFAc salt presence in self-assembly.
During our investigation, a surprising amount of residual TFA was found in batches of peptide
products. Peptides were synthesized using standard Fmoc-based SPPS, purified by prepHPLC on
a C18 column using increasing gradient of acetonitrile with 0.1% TFA or 0.1% acetic acid against
water with 0.1% TFA or 0.1% acetic acid, respectively. Purified peptides were lyophilized in water
1-3 times before being characterized by LC-MS (Figure S3 in Chapter 4), 1H NMR (Figure S14 in
Chapter 4),
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F NMR, and FTIR. Lyophilized peptides were dissolved in D2O and TFA

concentration was quantified using 19F NMR.

Figure 4.1. (A) Chemical structure of the proposed trifluoroacetate salt adducts formed with the
amine groups of peptide FFGALGLKGK. (B) 19F NMR spectra of 1mM peptide in D2O, and 1mM
TFA solution in D2O used to integrate the peak intensities.
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For peptides purified on the prepHPLC with 0.1% TFA containing solvents, 3.04 mM of
TFA was found per 1 mM of peptide, suggesting that TFA forms molar equivalent TFAc salts with
the 3 amine groups of the peptide (Figure 1). For peptides that were purified using 0.1% acetic
acid containing solvents, 0.39 mM of TFA was found per 1 mM of peptide, indicating that acetic
acid can displace some of the TFAc salts. However, acetate salts could also alter self-assembly of
peptides and quantification of acetate salt adducts formed with the peptide would require 1H NMR
which is more challenging to analyze than 19F NMR. Therefore, we continued this investigation
with peptides that were purified on prepHPLC with 0.1% TFA containing solvents. The 1:1 molar
ratio of amine to TFA was also observed in peptide GPKGLRGD that contains 3 amine groups,
and 2.91 mM TFA per 1 mM peptide was observed (data not shown).

4.2.1. Washing 20 mM peptide in 10 mM HCl
The TFAc were removed based on a modified protocol using HCl and verified by 19F NMR
and FTIR.6 10 mM HCl solution was chosen to assure peptide stability and personal safety while
handling large volumes of acidic solution.6 Briefly, lyophilized peptide was dissolved in aqueous
10 mM HCl solution to prepare a 20 mM peptide solution (about 20 mg/mL). The solution was
vortexed thoroughly at room temperature to allow protonation of the TFAc salts followed by
removal of solvent by vaporization or lyophilization to complete the first round of TFA removal
or “wash”. The procedure was repeated 1-4 times and peptides were subsequently dissolved in
D2O for 19F NMR and FTIR analysis. The unknown TFA concentration was quantified using 19F
NMR by integrating the area under the peak measured against 1 mM of TFA in D2O (Figure 2A).
After 4 rounds of washes, 113% molar equivalent TFA still remained which was also observed in
FTIR by the absorbance of TFA carbonyl peak at 1672 cm-1 (Figure 2B). These results indicated
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that TFAc-amine salt adducts form strong ionic bonds which could not be displaced by water or
dilute HCl.

Figure 4.2. 20 mM peptide washed 0-4 times with 10 mM HCl solution. One round of wash
indicates dissolving peptides in 10 mM HCl aqueous solution followed by removal of the solvent.
(A) 19F NMR spectra of 1 mM peptide dissolved in D2O show % of TFA per peptide molar ratio.
(B) Normalized FTIR spectra of 20 mM peptide dissolved in deuterated buffer (pH 7.4) show the
absorbance of carbonyl peak of TFA at 1672 cm-1.

4.2.2. Washing 1 mM peptide in 10 mM HCl
In order to displace the TFAc with chloride ion, a large excess of HCl to peptide-TFA ratio
was required. Therefore, the peptide concentration was decreased to 1 mM (about 1 mg/mL)
instead of increasing the HCl concentration to avoid destabilization of the peptide and corrosion
of lab equipment. The 19F NMR spectra show significant decrease in TFA concentration after one
wash, from over 300% molar ratio to 9.3%, and after 3 rounds of washes only 1.6% TFA remained
(Figure 3A). On the contrary, the TFA carbonyl peak at 1672 cm-1 was undetectable on FTIR after
the 1st wash (Figure 3B). The sensitivity range of each technique should be considered, with 22.6
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mM TFA being the lower limit for FTIR (Figure 2B, 4th wash) and 0.0003 mM TFA for 19F NMR
(data not shown).

Figure 4.3. 1 mM peptide washed 0-3 times with 10 mM HCl solution. One round of wash
indicates dissolving peptides in 10 mM HCl aqueous solution followed by removal of the solvent.
(A) 19F NMR spectra of 1 mM peptide dissolved in D2O show % of TFA per peptide molar ratio.
(B) Normalized FTIR spectra of 20 mM peptide dissolved in deuterated buffer (pH 7.4) show the
absorbance of carbonyl peak of TFA at 1672 cm-1.

4.3. TFAc adducts alter peptide self-assembly
Peptides were washed using 1 mM peptide in 10 mM HCl method and the TFA
concentration was quantified by 19F NMR. The washed and unwashed peptides were characterized
using FTIR, analysis of CAC, and MD simulations to study the self-assembly behavior, TEM and
AFM to compare morphology, and ζ-potential analysis to measure the surface charge potential.
Finally, the two peptides were incubated with MMP-9 to study the rate of enzyme hydrolysis.
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4.3.1. Disruption of intermolecular peptide bonds
The FTIR spectrum of unwashed peptide shows the characteristic TFA carbonyl peak at
1672 cm-1 (Figure 3) which disappears after the first wash. This peak directly overlaps with the
absorbance of peptide amide I band, which originates mainly from the C=O stretching of the
peptide and typically consists of a series of overlapping components bands, making it difficult to
accurately analyze the secondary structure without manipulating the data to subtract the TFA
contribution.7 However, we found that the presence of the TFAc physically changes the
supramolecular organization of the peptides, therefore, deriving the structure conformation
information by subtracting the TFA absorbance signal would be inappropriate for our system.
In order to resolve the individual components of the amide I band profile, curve fitting
analysis was performed and the best fit was achieved using the Levenberg Maquardt algorithm.
The spectral analysis of the unwashed peptide shows absorbance at 1678 and 1646 cm-1 (Figure
4A), whereas the washed peptides show peaks at 1666 and 1632 cm-1 which can be identified as
β-sheets, a strong peak centered at 1652 cm-1 that is exhibited by α-helices, and another peak at
1642 cm-1 that can be attributed to random coil arrangement of the peptide (Figure 4B). The
complete absence of 1672 cm-1 that is attributed to the TFA band confirms that TFA removal was
successful. The curve fitting analysis suggests that the TFAc interacts with the cationic amine
groups which hinders salt bridge formation and alters peptide back bone interactions and changes
the self-assembly behavior. Consequently, it was important for us to chemically remove the TFAc
in order to characterize the peptide nanostructures with minimal contribution from TFAc.
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Figure 4.4. Curve fitted FTIR of amide I region of unwashed (A) and washed (B) peptides after
subtracting the D2O background. (A) Unwashed peptides absorb at 1678 and 1646 cm-1 and (B)
washed peptides absorb at 1666, 1652, 1642, 1632 cm-1, demonstrating that the hydrogen bonding
pattern of the peptides are altered by presence of TFAc salts.

4.3.2. Induced aggregation of peptide nanostructures
Both TEM and AFM techniques show that the peptide with minimal amount of TFA selfassembles into individual fibers rather than bundles of fibers. For peptides containing 0.03% TFA,
discrete nanofibers about 5 nm in diameter were found evenly across the TEM grid (Figure 5A).
For peptides with 1.6% TFA, uniform sample of individual fibers were observed on the mica for
AFM (Figure 6A). On the contrary, peptides with 113% TFA formed indistinguishable fiber-like
aggregates (Figure 6B). Unwashed peptides containing 304% TFA dried in a fractal-like pattern
on the TEM grid (Figure 5B). This fractal pattern was also observed in AFM images of different
peptide sequences which caused an overall major challenge in imaging dried samples of peptide
nanostructures. The aggregation of the peptide structures is likely due to TFA which forms ionic
bonds with the positively charged lysine residues and prevents charge repulsion of the peptide
structures.
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Figure 4.5. (A) TEM images of 1 mM peptide containing 0.03% TFA self-assembled into
individual fibers of ~5 nm diameter. Scale bar 200 nm. (B) The same peptide with 304% TFA
forms aggregates and dried in a fractal pattern. Scale bar 1 µm.

Figure 4.6. (A) AFM images of 1 mM peptide containing 1.6% TFA also self-assembles into
discreet fibers. Scale bar 500 nm. (B) Peptides with 113% TFA forms aggregated fibers. Scale bar
200 nm.
Computational simulation using MARTINI8,9 coarse grain model agrees with the TEM and
AFM images and predicts that the peptide self-assembles into a network of thin, individual fibers,
each 3.5 nm in diameter, instead of forming thicker fiber bundles (Figure 7). The cross section of
the fiber shows the hydrophobic Phe residues (orange) are buried in the core of the fiber. The
cationic Lys residues (blue) decorate the fiber surface, thereby facing the water (Figure 7B). The
chloride ions that are represented in yellow form weak ionic bonds with Lys in water and the fibers
are still able to repel each other. However, if those anions are replaced with TFA, which can form
stable salt adducts with Lys residues in water, the positive charges are screened causing the fibers
to aggregate (Figure 6B).
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Figure 4.7. 500 ns simulation of (A-B) 30 mM and (C) 60 mM FFGALGLKGK in 12.5 nm3 water
box neutralized with 60 molecules of chloride, at 298°K and 1 bar. Phe residues are colored purple,
Lys residues are blue, Gly residues are grey, Ala and Leu residues are orange and chloride salts
are colored yellow.

4.3.3. Decrease in positive charges and increase in hydrophobicity
To confirm the decrease in positive charges of the peptide, ζ-potential analysis of the
unwashed and washed peptides was performed (Table 1). The ζ-potential was negative for
peptides containing 40-300% TFA. The negative ζ-potential is likely due to the free carboxylic
group of the peptide which gives the peptide molecule a net charge of -1 if all of the amine groups
are blocked by TFAc (in the case of 304% TFA) and becomes more positive as TFAc ions get
displaced by chloride ions during the 10 mM HCl washes. Finally, the ζ-potential of the washed
peptides increases to 2.2  0.5 mV which is comparable for the reported ζ-potential of 8.2  2.8
mV (peptide 2 AK in Chapter 3).
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Table 4.1. ζ-potential of 5 mM peptides in 2% PBS (pH 7.4) at 25C.

Next, we investigated the CAC of the unwashed and washed peptides using pyrene as a
solvatochromatic fluorophore. The 3:1 ratio which represents the hydrophobicity of the pyrene’s
environment is overall higher for the unwashed peptides with 304% TFA. This is likely due to the
TFAc adduct on the amine group of the N terminus which makes the diphenylalanine hydrophobic
core more lipophilic. Unexpectedly, the CAC of unwashed peptide increases to 0.5 mM in
comparison to the true value of 0.4 mM. Although the peptide is overall more hydrophobic with
TFAc adducts, the amphiphilicity of the peptide decreases when the hydrophobic TFAc binds to
the hydrophilic side. This change in the amphiphilic balance most likely causes the CAC to
increase, since now the main driving force is hydrophobic aggregation.

Figure 4.8. CAC of washed peptide (304% TFA) and unwashed peptide (0.03%TFA) determined
using pyrene in PBS (pH 7.4).
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4.3.4. Delays MMP-9-responsiveness
Lastly, we compared the MMP-9 hydrolysis rate of washed and unwashed peptide.
Previously, we have demonstrated that self-assembled nanostructures and the enzyme of interest
should be oppositely charged in order to optimize enzyme engagement through short-range
electrostatic interaction, and that highly ordered structures can hinder the enzyme’s accessibility
to the substrate. Here we observed that the hydrolysis of unwashed peptide is delayed compared
to the washed peptide (Figure 9).

Figure 4.9. 1 mM of washed peptide (1.6% TFA) and unwashed peptide (304% TFA) incubated
with 100 ng/mL MMP-9 in PBS (pH 7.4, supplemented with 1 mM CaCl2 and 55 µM ZnCl2) at
37°C.

4.4. Conclusions
We have demonstrated that the presence of residual TFAc significantly alters properties of
peptide nanostructures. TFA forms strong ionic bonds with the amine groups of the peptides in 1:1
molar ratio, which cannot be removed by lyophilization in water. This leads to large molar excess
of TFA per peptide molecule after synthesis, since many peptides contain at least one amine group
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on the N-terminus. In our system, the presence of TFA leads to a decrease in intermolecular
hydrogen and electrostatic interactions, which prevented fiber formation, increased the CAC,
rendered the ζ-potential negative, and delayed the hydrolysis of the peptide by MMP-9. Although
removing TFA can be a tedious and arduous task, having unknown concentrations of TFA in
different batches of peptides will lead to different self-assembly behavior and inevitably produce
irreproducible results as exemplified here and in literature.4,5 Especially in biomedical
applications, reproducibility of both morphology and size is crucial for translating the system for
potential use in clinical and commercial application. In addition, the residual TFA may cause
unanticipated cytotoxicity in biological assays. It is also worth noting that even commercial
peptides which costs extra for TFA removal were still found to contain TFA (data not shown).
Therefore, quantifying the amount of TFA present in a peptide batch by
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F-NMR and, if

necessary, removing residual TFA from the final peptide product should be implemented in the
general protocol for peptide synthesis. At the very least, the concentration of TFA should be
consistent in different peptide batches in order to reproduce the desired experimental results.
Finally, we encourage the readers to follow the protocol outlined in Supporting Information for a
successful removal of TFA.
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4.6. Methods
Solid Phase Peptide Synthesis (SPPS). Fluorenylmethyloxycarbonyl (Fmoc)-protected amino
acids and pre-loaded Wang resins were purchased from Bachem. Peptides were synthesized on
CEM Liberty Blue microwave assisted solid phase peptide synthesizer using ~1:5 resin to amino
acid

ratio

and

excess

of

diisopropylcarbodiimide

(DIC),

Oxyma

(Ethyl(hydroxyimino)cyanoacetate), and 20% piperidine in dimethylformamide (DMF). The
complete peptide-loaded resins were washed three times in dichloromethane, followed by three
washes in diethyl ether on a filtration column. The peptides were cleaved from the resins and side
chain protecting groups were removed by reacting with TFA cocktail (95% trifluoroacetic acid,
2.5% triisopropyl silane, and 2.5% water) for 2 h. The cleaved peptides were recovered by
removing TFA cocktail, followed by precipitation in cold diethyl ether. Peptides were washed three
times in cold diethyl ether, using centrifugation to collect the precipitated crude peptide.
Preparatory High-Performance Liquid Chromatography (HPLC). Crude peptides were
dissolved in 5% acetonitrile in water containing 0.1% TFA or 0.1% acetic acid and purified through
a preparatory C18 column on the Thermo Scientific Dionex Ultimate 3000 using 5-50% acetonitrile
(+ 0.1% TFA or acetic acid) gradient in water (+ 0.1% TFA or acetic acid).
19F

NMR. Sample solutions were prepared by dissolving peptide powder into D2O. Peptide

powder was prepared by washing 1 mM peptide 0-3 times with 10 mM HCl, or by washing 20
mM peptide 0-4 times with 10 mM HCl. 500L of sample solutions (1 or 0.5 mM peptide) were
placed in 5mm NMR tubes. 19F NMR experiments were performed on a Bruker AVANCE HD III
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700 MHz spectrometer equipped with a 5-mm QCI-F cryoprobe at a frequency of 658.79 MHz.
All 19F spectra were acquired were acquired locked and at 25 °C. Typical 1D 19F NMR acquisition
parameters were as follows: 8.0 ms pulse length (60° flip angle), 100 ppm sweep width (65,789
Hz) centered at -80 ppm, 0.50 sec acquisition time, 2 sec relaxation delay time, and 256 scans (11
min). 1D 19F NMR spectra were processed with 5 Hz exponential line broadening and visualized
using TopSpin 3.5.
Computational Simulation. The MARTINI force field8,9 was applied to model peptide selfassembly using the GROMACS molecular dynamics package.10 This force field utilizes a 4-to-1
atom:CG-bead mapping to represent protein backbone and side chains (and a 2-3:1 atom:CG-bead
mapping for ring systems). A cubic box with 30 peptide molecules, placed randomly with a
minimum distance of 3 Å between them, was solvated in standard MARTINI CG water (4 water
molecules per bead) to a final concentration of approximately 30 mM. The resulting net charge
was neutralized by adding 60 molecules of chloride to the box. A Berendsen thermostat and
barostat were used to keep the temperature at 298K and pressure at 1 bar, respectively.11 The box
was energy minimized using the steepest descent integrator and then equilibrated for 6.25x106 time
steps of 20 fs. The total simulation time equates 125 ns, but due to the smoothness of the CG
potentials, this roughly equates to an effective 500 ns of atomistic simulation time.12
Fourier-Transform Infrared Spectroscopy (FTIR). Sample solutions were prepared by
dissolving peptide powder into D2O using vortex followed by sonication at room temperature for
10 min. Peptide powder was prepared by washing 1 mM peptide 0-3times with 10 mM HCl, or by
washing 20 mM peptide 0-4 times with 10mM HCl. 10 L of sample solutions (20 mM peptide)
were drop casted between two CaF2 cells with PTFE spacers (12 m thickness x 13 mm diameter).
Absorbance spectra were taken from 4000 cm-1 to 800 cm-1 with 64 scans at 4 cm-1 resolution on
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the Bruker Vertex 70 spectrometer. For analysis in Figures 2-3, D2O absorbance spectra was
subtracted from the sample absorbance and graphed from 1550 to 1750 cm-1. For analysis in Figure
4, curve fitting analysis was performed to resolve the individual components of the amide I band
profile. Input parameters such as the estimated number of components bands, their positions and
widths were selected. To increase the digital resolution spectrum was post zerofilled by an
additional factor of 8. The best fit was achieved with the Levenberg Maquardt algorithm with
which yielded the lowest residual RMS error value of 0.000148.
Transmission Electron Microscopy (TEM). TEM images were taken on FEI Titan Halo 80-300
microscope. 1 mM of peptide solution was prepared in 10 mM phosphate buffer (pH 7.4) sonicated
for 10 min and 5 L of the solution was drop casted on a carbon film grid (400 mesh, copper) and
dried completely. To the dry grid, 5 L of MilliQ water was drop casted and quickly blotted to
wash away the phosphate salts and dried completely. Finally, 5 L of methylamine vanadate based
negative stain (NanoVan® by Nanoprobes) was drop casted, blotted away, and dried completely.
Atomic Force Microscopy (AFM). Sample solutions were prepared by dissolving peptide powder
into 10 mM phosphate buffer (pH 7.4) using vortex followed by sonication at room temperature
for 10 min. Peptide powder was prepared by washing 1 mM peptide 3 times with 10 mM HCl
(Figure 6A) or 20 mM peptide 4 times with 10 mM HCl (Figure 6B). 5 L of sample solutions
were drop casted on freshly cleaved mica and allowed to dry for 48 h before imaging. AFM images
were taken on Bruker Dimension FastScan using FASTSCAN-B tip on fast scan mode.
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Chapter 5
MMP-9-Responsive Peptide Nanocarriers for Encapsulation of Metallodrugs

5.1. Introduction
Despite the plethora of cancer treatments available, which include surgery, radiation,
chemotherapeutics, targeted therapies, and immunotherapy, there will be an estimate of 0.6 million
cancer deaths in US in 2019.1 In search for novel cancer chemotherapeutics, both organic and
metal-based compounds are being developed and investigated. In the field of metallodrugs, the
most widely used drug is cisplatin that has been used for treatment of cancer since the 1970’s.
Cisplatin and the follow up drugs, carboplatin and oxaliplatin, have a long history of use in
treatment of ovarian, testicular, bladder, head and neck, and non-small cell lung cancers for the
past 40 years.2 Although popular in clinical use, their effectiveness is still hindered by many
problems including poor solubility, quick clearance, a limited spectrum of activity, acquired or
intrinsic resistance, and a lack of selectivity leading to high nephrotoxicity and crippling adverse
side effects in patients.2 To overcome these shortcomings, new platinum(IV) pro-drugs such as
ormaplatin, iproplatin, and satraplatin have undergone clinical trials but have not yet been
approved by the US FDA.3
Additionally, it is important to explore metallodrugs (denominated as unconventional)
based on metals other than platinum which display modes of action4 that are different from
cisplatin,5–7 as well as their effects in the immune system.8 Current efforts have also been focused
on developing agents that can be photoactivated9 or delivery systems that may improve their
pharmacological profiles.10 Examples of unconventional metallodrugs in phase I/II clinical trials
include a ruthenium-based compound, NAMI-A,3 for treatment of colorectal cancer, and a
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photodynamic compound (TLD-1433) that was studied succesfully in Phase Ib clinical trials for
non-muscle invasive bladder cancer and has now entered Phase II clinical trials.9 More recently,
copper(II)-casiopeina and copper(I) (HydroCuP) compounds have entered Phase I clinical trials,
and a gold based drug, auranofin, is being investigated to be repurposed for the treatment of
leukemia, small lung and ovarian cancer.11-13 However, for all small molecule-based drugs, it is
imperative that they reach the tumor sites and enter the cancer cells. In order to improve on the
efficacy and selectivity of molecular drugs, formulations using nanomaterials have become
increasingly popular.
Nanomedicine takes advantage of its particle size (1-500nm) and surface properties to
accumulate selectively in the tumor microenvironment through leaky blood vessels that causes the
enhanced permeability and retention effect.14 This passive targeting mechanism is used by
Lipoplatin, a liposomal formulation of cisplatin in phase III clinical trial, to prolong circulation
lifetime and to increase tumor uptake of cisplatin.15 In addition to passive targeting, nanomedicine
can be designed to actively target tumor cells using various endogenous stimuli such as pH,
antibodies, integrins, and enzymes that are characteristic of cancer cells.16 Of the endogenous
stimuli, the up-regulation of matrix metalloproteinases (MMPs) have been observed in almost all
types of cancers, including ovarian cancer, and the roles of the enzymes have been associated to
cancer invasion and metastasis.17–19 More details in passive and active targeting nanomaterials can
be found in Chapter 2, and MMP-responsive nanomaterials can be found in Chapter 3. Therefore,
MMP-9 is a suitable cancer specific bio-target and the enzyme action can be exploited to produce
a desirable response, such as disassembly in the presence of MMP-9 to achieve site specific release
of payloads.20
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Using previously described MMP-9-responsive peptide nanostructures in Chapter 5, we
have encapsulated unconventional metal-based compounds with high anti-cancer properties to
create a novel metallodrug-loaded nanocarriers. This system will allow payloads to be selectively
released in the tumor microenvironment where MMP-9 is overexpressed, while controlling the
rate of drug release by controlling the kinetics of MMP-9 hydrolysis of the peptide nanocarriers.
Upon MMP-9 cleavage, the nanocarriers will disassemble to release the payloads and biodegrade
into amino acids (Figure 1).

5.2. Design of metallodrug-loaded nanocarriers
Our group at Brooklyn College is focused on studying metal-based compounds for kidney
cancer for which renal cell carcinoma (RCC) constitutes the most common type. Currently there
are no efficient treatment options for advanced stage and metastatic RCC, since pharmacological
interventions such as chemotherapy, targeted therapy or immunotherapy are very limited and only
improve survival rates in periods of 9 to 20 months. Our group has developed a number of metalbased compounds that have demonstrated enormous potential as chemotherapeutics against renal,
colorectal and prostate cancers (including mechanistic and in vivo studies). These compounds
include bimetallic compounds that incorporate the gold(I) compounds containing phosphanes21–24
or N-heterocyclic carbene ligands25–27 and a second metallic fragment being titanocenes or
ruthenium(II)-arene based complexes (Ti-Au and Ru-Au compounds). Gold(I) compounds
containing either phosphanes28 or N-heterocyclic carbenes29,30 are emergining as derivatives with
enormous potential as chemotherapeutic agents.
For this project, we chose two gold(I) compounds that contain N-heterocyclic carbenes that
were found to have relevant anti-cancer properties in many different cell lines (Figure 1). The
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compounds are ([AuX(NHC)]); NHC = 1,3-dibenzyl-4,5-diphenylimidazol-2-ylidene NHC-Bn; X
= Cl A; 1,3-diethyl-4,5,-diphenylimidazol-2-ylidene NHC-Et; X = Br B).31,32 These compounds
contain 4,5-diarylimidazoles cores with well-known pharmacological properties.33 Compound A
(described by Tacke et al.) and a variation with the 2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyl1’-thiolate showed very good activity against a wide range of human cancer cell lines from the
NCI 60 cell line panel, and relevant tumor growth inhibition in vivo for a human clear cell renal
carcinoma Caki-1 xenograft mice model.31,34,35 Compound B, described by Gust et al. in 2011,
was found to be cytotoxic (low or sub-micromolar range) in breast and colon cancer cell lines.32

Figure 5.1. Cartoon representation of cancer targeted release of metallodrugs (compounds A and
B) from biodegradable MMP-9-responsive peptide nanocarriers. Chemical structures of Nheterocyclic carbene containing gold(I) based compounds with relevant anti-cancer
properties.31,32,35
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In addition, modifications of compounds A and B showed improved anti-cancer activities.
We have coordinated the [Au(NHC)]+ fragments of compounds A and B to [Ti(Cp)2M] fragments
through a dual linker (-OC(O)-p-C6H4-S-) containing both a carboxylate and a thiolate group.47
The new compounds have been efficacious in vitro against human clear-cell renal carcinoma Caki1 and human prostate PC3 cells while being apoptotic and inhibiting migration, inhibition of
thioredoxin reductase (TrRx) and vascular endothelial growth factor (VEGF) in prostate PC3
cancer cell lines.47 In another example, an antibody drug conjugate (ADC) of compound A with
an engineered antibody (Thiomab LC-V2050) via cysteine conjugation, showed moderate
improvement of anti-proliferative activity in HER2 positive breast cancer cell line, in comparison
to the non-conjugated drug.21

Figure 5.2. Chemical structures of peptide 1 PK and 1 PD, and cartoon representations and pre
and post MMP-9 hydrolysis of peptide nanocarriers. 80% of 1 PK is cleaved by MMP-9 in 48 h
whereas less than 10% of 1 PD is cleaved in 96 h (described in Chapter 3).
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Although compounds A and B show potential anti-cancer activity, both drugs are highly
insoluble in water and DMSO which makes it difficult to treat cancer cells in vitro or to admister
them as solutions in vivo. Therefore, we sought out to encapsulate compounds A and B in MMP9-responsive peptide nanocarriers to solubilize the compounds in phsyiological conditions which
could potentially increase the efficacy of the drugs (Figure 1). As examined in Chapter 3, tumor
tissues from patients with renal cell carcinoma show significantly higher expression of MMP-9
mRNA, with increasingly higher expression in advanced tumor stages.36 We hypothesize that by
encapsulating the metallodrugs, which are highly active against this type of cancer, we can control
the spatial and temporal release of the compounds based on MMP-9 activity, and increase the
selectivity of these compounds.
For the nanocarriers, we chose self-assembling peptides 1 PK and 1 PD, previously
described in Chapter 3, which form ~200 nm long bundles of worm-like micelles with a
hydrophobic core and a cationic or anionic hydrophilic tail (Figure 2). Full characterization of the
peptide nanostructures can be found in Chapter 3. The anionic nanostructure, 1 PD, was found to
have slow response to MMP-9, due to the electrostatic repulsion between the anionic nanostructure
and the negatively charged MMP-9. On the contrary, the analogous cationic nanostructure, 1 PK,
readily engages with MMP-9 and is cleaved to become the enzymatic product, 1 P, which no
longer forms a self-assembled nanostructure (Figure 3). Using 1 PK and 1 PD to encapsulated
compounds A and B, we can investigate how the rate of MMP-9 responsiveness could effect the
performance of the compounds in the biological setting.
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5.3. Encapsulation of metallodrugs
The encapsulation efficiency of compounds A and B by peptide nanocarrier 1 PD was
investigated. Metal based drugs are advantageous as cytotoxic payloads in nanomedicine because
the metal element can be precisely quantified by inductively-coupled plasma optical emission
spectrometry (ICP-OES) or atomic absorption spectrometry (AAS). To quantify the amount of
compounds A and B, samples were digested in concentrated nitric acid prior to analysis.

5.3.1. Digestion of gold-based compounds
The concentrations of the compounds A and B were analyzed using ICP-OES at 242.8 nm
and 267.6 nm and measured against calibration curve of 0.01 - 1 mg/L Au standard prepared in
aqueous 5% HNO3. In order to detect the elemental gold, compounds A and B were digested in
concentrated nitric acid prior to analysis. First, a stock solution of 0.05 mM compound B was
prepared in acetonitrile and was refluxed in concentrated nitric acid for 15 min, 30 min, or 60 min
at 100°C. The digested samples were diluted 200 times in 10% HCl

(aq)

solution to achieve final

concentrations within the range of calibration curve in a total of 5% HNO3 and 10% HCl aqueous
solution. The measured mg/l values were calculated into mM and multiplied by the dilution factor
to compare to the stock solution (Table 1). Higher concentrations of Au was detected with longer
refluxing times. After 1 h, 0.045 mM of Au was detected in comparison to the actual 0.05 mM that
should have been measured. A second stock solution of 0.075 mM compound B was prepared in
acetonitrile and refluxed for 2 h or heated until dryness. The refluxed sample was diluted in 10%
HCl

(aq)

and the dry samples were dissolved in 5% HNO3 and 10% HCl acqueous solution and

diluted 100 times. For both methods, the detected Au was near 0.075 mM, which suggests that 2
h or longer is sufficient time to digest all of compound B. Likewise, the accurate amount of
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compound A was also detected when digested until dryness. Moving forward, we decided to digest
compounds A and B by heating it until dryness in order to minimize errors from losing volume
during reflux that will lead to incorrect dilution factor.

Table 5.1. ICP-OES analysis of 0.05 mM or 0.075 mM compound B refluxed in concentrated
nitric acid at 100°C over time or heated until dryness. The reported concentrations of Au were
measured at 267.6 nm and 242.8 nm, and multiplied by the dilution factor.

5.3.2. Encapsulation efficacy of peptide nanocarriers
Next, the encapsulation efficiency of the compounds in peptide nanocarriers was
investigated following the procedure described in Figure 3. Briefly, peptides were dissolved in 10
mM phosphate buffer and the pH was adjusted to 7.4 using 0.5 mM HCl or NaOH to make 2 mM
peptide solution. To the peptide solution, stock drug solution (prepared in acetonitrile) was added
for a final concentration of 1 mM peptide and 100, 10, 1, or 0.1 µM of drug in 1:1 ratio of buffer
and acetonitrile. The mixture was vortexed and sonicated for 20 min and dried to a film then
suspended in phosphate buffer and sonicated for 20 min. The non-encapsulated, hydrophobic drug
was separated from the suspended drug-loaded peptide nanocarriers by centrifugation and the
supernatant was collected. The Au content in the supernatant was digested in concentrated nitric
acid as described above, and analyzed by ICP-OES or AAS. The encapsulation efficiency of
compounds A and B by 1 PD was similar for lower concentrations. Interestingly, 91% and 100%
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of 10 µM compounds A and B were encapsulated, respectively, whereas only 23% and 24% of 1
µM compounds A and B were encapsulated. At 100 µM, 61% of compound A and 20% of
compound B was encapsulated by 1 PD, likely due to the higher hydrophobicity of compound A.

Figure 5.3. Encapsulation of metallodrugs in peptide nanocarriers. Step 1) Prepare 2 mM peptide
stock solution in 10 mM phosphate buffer and adjust the pH to 7.4 using 0.5 mM HCl or NaOH.
Prepare 200, 20, 2, 0.2 M drug stock concentrations in acetonitrile. Step 2) In 1.5 mL centrifugal
tubes, combine 100 L of aqueous peptide solution with 100 L of the drug stock solution for a
final concentration of 1 mM peptide and 100, 10, 1, 0.1 M of drug in 1:1 ratio of buffer and
acetonitrile. Vortex the mixture and sonicate for 20 min. Step 3) Remove solvents compeltely
under pressure. Step 4) Add 200 L of 10 mM phosphate buffer to the dried film to suspend the
peptide-drug mixture. Gently vortex the aquesous mixture and sonicate for 20 min. Step 5)
Separate the non-encapsulated, hydrophobic drug from the suspended peptide-drug nanocarriers
by centrifugation (10,000 rpm for 10 sec). Collect 200 L of supernatant for analysis and
characterization.
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Table 5.2. Encapsulation efficiency of 1 mM 1 PD with compounds A and B.

5.4. Molecular dynamic simulations
In order to investigate the interactions between the metallodrugs and the peptides,
dynamic simulations were performed. The structures of compounds A and B were initially
optimized by using a computational approach based on the framework of the density functional
theory (DFT), which has been widely exploited in studying the properties and reactivity
metallodrugs.37–40 DFT methods encompass a wide range of approximations that leads to the socalled density functionals, usually defined as pure, hybrid and range-separated hybrid depending
on the theoretical treatment of the electron cloud.41 Herein, we have used PBE0,42 that have
previously demonstrated to provide reliable results for structural and reactive properties gold(I)based organometallic compounds.43,44
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Figure 5.4. Optimized structures for compounds A and B at the selected DFT level of theory
(PBE0-D3/def2-SVP). Molecules are represented in ball and stick model. Color scheme: hydrogen
in white, carbons in grey, nitrogen in blue, chloride in green, bromide in red and gold in yellow.

Next, we assessed the interaction of the metallodrugs with peptides 1 PK/PD and 2 PK/PD
for comparison. Peptides were built up with the Protein Preparation Wizard module implemented
in Maestro45 and protonation states of all side chains were defined at pH 7 by using PROPKA
3.1.46 As illustrated in Figure 2, (1) the resulting peptides are located at the vicinity of the
metallodrug (3.5 angstroms of distance). Aiming to mimic the conditions in solution and accurately
correct solvent effects, (2) the model system is embedded in box filled with water molecules.
Sodium cations or chlorides anions were added to counterbalance the total electric charge in of the
peptides. Additional sodium and chloride ions were added as well to reproduce the physiological
NaCl salt concentration of 0.15 M, so that our simulations can be extrapolated to real in vivo
conditions.
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(1)

(2)

(4)

(3)

Figure 5.5. We illustrate the main steps of the MD workflow: (1) the peptide-compound B model
is built up; (2) the systems is embedded in a water box; (3) MD simulations run for 100 ns, where
the evolution of atoms are monitored by plotting the root-mean-square deviation (RMSD); (4) the
equilibrated peptide-compound pair is extracted from the trajectory for further quantum
mechanical calculations.
Four systems are simulated: compound B with the peptides 1 PK, 1 PD, 2 PK, and 2 PD
(peptide sequences can be found in Table 3). In MD trajectories, the root-mean-square deviation
(RMSD) of atomic positions can be used to assess the average distance between atoms during the
simulation, that is, the stability of the system. As shown in Figure 7, the structure of compound B
is fairly stable during the whole simulation (red line), with a change of less than 1 Å only form the
very beginning of the four simulations. A dissimilar behavior is observed for peptides. A close
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inspection of Figure 7 reveals that the associated RMSD to peptides significantly increase during
the first ns of the simulation, which quickly raised up to 10-12 Å. This is the logical consequence
of the larger flexibility of peptides. However, such oscillations are attenuated after 2-5 ns. Indeed,
although blue lines demonstrated that the peptides are more flexible during the whole simulations,
the RMSD for peptides are restricted to 6±2 Å in the last part of the trajectory.

Figure 5.6. Root-mean-square deviation (RMSD) of compound B with Peptides 1 PK/PD and 2
PK/PD in angstroms. RMSD for the compound are plotted in red, and for peptides in blue.

Our computational study is completed by extracting the compound B-peptide pairs from
the trajectory to compute their interaction energies at DFT level (Table 3). It is worth stressing that
compound B and 2 PK remains unbound at the end of the MD simulation, and consequently we
cannot compute the pairwise energy.

134

Table 5.3. Calculated interaction energy of compound B-peptide pairs.

5.5. Conclusion
In conclusion, we have demonstrated a proof-of-concept in which peptide nanostructures
can be used to encapsulate metallodrugs. The highest concentration of compounds A and B
encapsulated by 1 PD are only about 60 and 20 µM. According to the computational studies, 1 PD
should have the highest stability with compound B and we can expect the drug loading capacity
of 1 PK and 2 PD to be lower and weakest with 2 PK. However, the IC50 values of these
compounds are well below 20 µM and higher drug concentrations are not necessary. In addition,
the compounds are completely soluble within the nanocarrier which could lead to even smaller
IC50 values since the unencapsulated drugs are highly hydrophobic and precipitates easily.
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5.7. Methods
Atomic absorption spectroscopy (AAS). Digested samples were measured on a Perkin Elmer
Analyst 800 using a transversely heated graphite furnace (THGA) system at 242.8 nm.
Inductively coupled-plasma optical emission spectroscopy (ICP-OES). Digested samples were
measured Perkin Elmer-Optima 7000DV ICP-OES at 242.795 nm and 267.595 nm.

5.8. References
(1)

Cancer Facts & Figures 2019 | American Cancer Society

https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-factsfigures-2019.html (accessed Apr 4, 2019).
(2)

Kelland, L. The Resurgence of Platinum-Based Cancer Chemotherapy. Nat. Rev. Cancer

2007, 7 (8), 573–584. https://doi.org/10.1038/nrc2167.
(3)

Johnstone, T. C.; Suntharalingam, K.; Lippard, S. J. The Next Generation of Platinum

Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016,
116 (5), 3436–3486. https://doi.org/10.1021/acs.chemrev.5b00597.
(4)

Metallo-Drugs: Development and Action of Anti-Cancer Agents, A. Sigel, H. Sigel, E.

Freisinger, R.K.O. Sigel (Eds.), Vol. 18 of Metal Ions in Life Sciences [ISSN: 1559-0836, ISSN
(Electronic) 1868-0402], Walter de Gruyter GmbH, Berlin/Boston, 2018, 546 Pp [ISBN: 978-311-046984-4; 978-3-11-047073-4 (Electronic PDF); 978-3-11-046990-5 (Electronic EPUB). SetISBN: 978-3-11-047074-1]. DOI Https://Doi.Org//10.1515/9783110470734. Coord. Chem. Rev.
2018, 371, 96–98. https://doi.org/10.1016/j.ccr.2018.05.018.
(5)

Metal-Based Anticancer Agents; 2019.

(6)

Allardyce, C. S.; Dyson, P. J. Metal-Based Drugs That Break the Rules. Dalton Trans

2016, 45 (8), 3201–3209. https://doi.org/10.1039/C5DT03919C.
(7)

Liang, J.-X.; Zhong, H.-J.; Yang, G.; Vellaisamy, K.; Ma, D.-L.; Leung, C.-H. Recent

Development of Transition Metal Complexes with in Vivo Antitumor Activity. J. Inorg.
Biochem. 2017, 177, 276–286. https://doi.org/10.1016/j.jinorgbio.2017.06.002.

136

(8)

Englinger, B.; Pirker, C.; Heffeter, P.; Terenzi, A.; Kowol, C. R.; Keppler, B. K.; Berger,

W. Metal Drugs and the Anticancer Immune Response. Chem. Rev. 2019, 119 (2), 1519–1624.
https://doi.org/10.1021/acs.chemrev.8b00396.
(9)

Monro, S.; Colón, K. L.; Yin, H.; Roque, J.; Konda, P.; Gujar, S.; Thummel, R. P.; Lilge,

L.; Cameron, C. G.; McFarland, S. A. Transition Metal Complexes and Photodynamic Therapy
from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the
Development of TLD1433. Chem. Rev. 2018. https://doi.org/10.1021/acs.chemrev.8b00211.
(10)

Poursharifi, M.; Wlodarczyk, M. T.; Mieszawska, A. J. Nano-Based Systems and

Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy. Inorganics 2019, 7 (1),
2. https://doi.org/10.3390/inorganics7010002.
(11)

Silva-Platas, C.; Villegas, C. A.; Oropeza-Almazán, Y.; Carrancá, M.; Torres-

Quintanilla, A.; Lozano, O.; Valero-Elizondo, J.; Castillo, E. C.; Bernal-Ramírez, J.; FernándezSada, E.; et al. Ex Vivo Cardiotoxicity of Antineoplastic Casiopeinas Is Mediated through
Energetic Dysfunction and Triggered Mitochondrial-Dependent Apoptosis. Oxid. Med. Cell.
Longev. 2018, 2018, 8949450–8949450. https://doi.org/10.1155/2018/8949450.
(12)

Gandin, V.; Ceresa, C.; Esposito, G.; Indraccolo, S.; Porchia, M.; Tisato, F.; Santini, C.;

Pellei, M.; Marzano, C. Therapeutic Potential of the Phosphino Cu(I) Complex (HydroCuP) in
the Treatment of Solid Tumors. Sci. Rep. 2017, 7 (1), 13936. https://doi.org/10.1038/s41598017-13698-1.
(13)

Intervention Dynamic Trial Listing Page https://www.cancer.gov/about-

cancer/treatment/clinical-trials/intervention/auranofin (accessed Apr 4, 2019).
(14)

Schroeder, A.; Heller, D. A.; Winslow, M. M.; Dahlman, J. E.; Pratt, G. W.; Langer, R.;

Jacks, T.; Anderson, D. G. Treating Metastatic Cancer with Nanotechnology. Nat. Rev. Cancer
2012, 12 (1), 39–50. https://doi.org/10.1038/nrc3180.
(15)

Stathopoulos, G. P.; Boulikas, T.; Stathopoulos, G. P.; Boulikas, T. Lipoplatin

Formulation Review Article, Lipoplatin Formulation Review Article. J. Drug Deliv. J. Drug
Deliv. 2011, 2012, 2012, e581363. https://doi.org/10.1155/2012/581363, 10.1155/2012/581363.
(16)

Blum, A. P.; Kammeyer, J. K.; Rush, A. M.; Callmann, C. E.; Hahn, M. E.; Gianneschi,

N. C. Stimuli-Responsive Nanomaterials for Biomedical Applications. J. Am. Chem. Soc. 2015,
137 (6), 2140–2154. https://doi.org/10.1021/ja510147n.

137

(17)

Egeblad, M.; Werb, Z. New Functions for the Matrix Metalloproteinases in Cancer

Progression. Nat. Rev. Cancer 2002, 2 (3), 161–174. https://doi.org/10.1038/nrc745.
(18)

Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of Matrix Metalloproteinases in

Cancer Progression and Their Pharmacological Targeting: MMPs as Potential Targets in
Malignancy. FEBS J. 2011, 278 (1), 16–27. https://doi.org/10.1111/j.1742-4658.2010.07919.x.
(19)

Davidson, B.; Goldberg, I.; Gotlieb, W. H.; Kopolovic, J.; Ben-Baruch, G.; Nesland, J.

M.; Berner, A.; Bryne, M.; Reich, R. High Levels of MMP-2, MMP-9, MT1-MMP and TIMP-2
MRNA Correlate with Poor Survival in Ovarian Carcinoma. Clin. Exp. Metastasis 1999, 17 (10),
799–808. https://doi.org/10.1023/A:1006723011835.
(20)

Zelzer, M.; Todd, S. J.; Hirst, A. R.; McDonald, T. O.; Ulijn, R. V. Enzyme Responsive

Materials: Design Strategies and Future Developments. Biomater Sci 2013, 1 (1), 11–39.
https://doi.org/10.1039/C2BM00041E.
(21)

González-Pantoja, J. F.; Stern, M.; Jarzecki, A. A.; Royo, E.; Robles-Escajeda, E.;

Varela-Ramírez, A.; Aguilera, R. J.; Contel, M. Titanocene–Phosphine Derivatives as Precursors
to Cytotoxic Heterometallic TiAu2 and TiM (M = Pd, Pt) Compounds. Studies of Their
Interactions with DNA. Inorg. Chem. 2011, 50 (21), 11099–11110.
https://doi.org/10.1021/ic201647h.
(22)

Fernández-Gallardo, J.; Elie, B. T.; Sulzmaier, F. J.; Sanaú, M.; Ramos, J. W.; Contel, M.

Organometallic Titanocene–Gold Compounds as Potential Chemotherapeutics in Renal Cancer.
Study of Their Protein Kinase Inhibitory Properties. Organometallics 2014, 33 (22), 6669–6681.
https://doi.org/10.1021/om500965k.
(23)

Elie, B. T.; Fernández-Gallardo, J.; Curado, N.; Cornejo, M. A.; Ramos, J. W.; Contel,

M. Bimetallic Titanocene-Gold Phosphane Complexes Inhibit Invasion, Metastasis, and
Angiogenesis-Associated Signaling Molecules in Renal Cancer. Eur. J. Med. Chem. 2019, 161,
310–322. https://doi.org/10.1016/j.ejmech.2018.10.034.
(24)

Mui, Y. F.; Fernández-Gallardo, J.; Elie, B. T.; Gubran, A.; Maluenda, I.; Sanaú, M.;

Navarro, O.; Contel, M. Titanocene–Gold Complexes Containing N-Heterocyclic Carbene
Ligands Inhibit Growth of Prostate, Renal, and Colon Cancers in Vitro. Organometallics 2016,
35 (9), 1218–1227. https://doi.org/10.1021/acs.organomet.6b00051.
(25)

Massai, L.; Fernández-Gallardo, J.; Guerri, A.; Arcangeli, A.; Pillozzi, S.; Contel, M.;

Messori, L. Design, Synthesis and Characterisation of New Chimeric Ruthenium(II)–Gold(I)
138

Complexes as Improved Cytotoxic Agents. Dalton Trans. 2015, 44 (24), 11067–11076.
https://doi.org/10.1039/C5DT01614B.
(26)

Fernández-Gallardo, J.; Elie, B. T.; Sanaú, M.; Contel, M. Versatile Synthesis of Cationic

N-Heterocyclic Carbene–Gold(I) Complexes Containing a Second Ancillary Ligand. Design of
Heterobimetallic Ruthenium–Gold Anticancer Agents. Chem. Commun. 2016, 52 (15), 3155–
3158. https://doi.org/10.1039/C5CC09718E.
(27)

Elie, B. T.; Pechenyy, Y.; Uddin, F.; Contel, M. A Heterometallic Ruthenium–Gold

Complex Displays Antiproliferative, Antimigratory, and Antiangiogenic Properties and Inhibits
Metastasis and Angiogenesis-Associated Proteases in Renal Cancer. JBIC J. Biol. Inorg. Chem.
2018. https://doi.org/10.1007/s00775-018-1546-8.
(28)

Bertrand, B.; Casini, A. A Golden Future in Medicinal Inorganic Chemistry: The Promise

of Anticancer Gold Organometallic Compounds. Dalton Trans. 2014, 43 (11), 4209–4219.
https://doi.org/10.1039/C3DT52524D.
(29)

Zou, T.; Lum, C. T.; Lok, C.-N.; Zhang, J.-J.; Che, C.-M. Chemical Biology of

Anticancer Gold(III) and Gold(I) Complexes. Chem. Soc. Rev. 2015, 44 (24), 8786–8801.
https://doi.org/10.1039/c5cs00132c.
(30)

Mora, M.; Gimeno, M. C.; Visbal, R. Recent Advances in Gold–NHC Complexes with

Biological Properties. Chem. Soc. Rev. 2019, 48 (2), 447–462.
https://doi.org/10.1039/C8CS00570B.
(31)

Hackenberg, F.; Müller-Bunz, H.; Smith, R.; Streciwilk, W.; Zhu, X.; Tacke, M. Novel

Ruthenium(II) and Gold(I) NHC Complexes: Synthesis, Characterization, and Evaluation of
Their Anticancer Properties. Organometallics 2013, 32 (19), 5551–5560.
https://doi.org/10.1021/om400819p.
(32)

Liu, W.; Bensdorf, K.; Proetto, M.; Abram, U.; Hagenbach, A.; Gust, R. NHC Gold

Halide Complexes Derived from 4,5-Diarylimidazoles: Synthesis, Structural Analysis, and
Pharmacological Investigations as Potential Antitumor Agents. J. Med. Chem. 2011, 54 (24),
8605–8615. https://doi.org/10.1021/jm201156x.
(33)

Marzo, T.; Cirri, D.; Gabbiani, C.; Gamberi, T.; Magherini, F.; Pratesi, A.; Guerri, A.;

Biver, T.; Binacchi, F.; Stefanini, M.; et al. Auranofin, Et3PAuCl, and Et3PAuI Are Highly
Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. ACS Med. Chem. Lett.
2017, 8 (10), 997–1001. https://doi.org/10.1021/acsmedchemlett.7b00162.
139

(34)

Dada, O.; Curran, D.; O’Beirne, C.; Müller-Bunz, H.; Zhu, X.; Tacke, M. Synthesis and

Cytotoxicity Studies of Novel NHC–Gold(I) Pseudohalides and Thiolates. J. Organomet. Chem.
2017, 840, 30–37. https://doi.org/10.1016/j.jorganchem.2017.03.050.
(35)

Walther, W.; Dadac, O.; O128;TMBeirnec, C.; Ott, I.; Sanchez-Sanz, G.; Schmidt, C.;

Werner, C.; Zhu, X.; Tacke, M. In Vitro and In Vivo Investigations into the Carbene Gold
Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR. Lett.
Drug Des. Discov. 2017, 14 (2), 125–134.
(36)

Qiao, Z.; Li, Y.; Lu, H.; Wang, K.; Xu, W. Expression of Tissue Levels of Matrix

Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Renal Cell Carcinoma. World
J. Surg. Oncol. 2013, 11, 1. https://doi.org/10.1186/1477-7819-11-1.
(37)

Alberto, M. E.; Lucas, M. F.; Pavelka, M.; Russo, N. The Degradation Pathways in

Chloride Medium of the Third Generation Anticancer Drug Oxaliplatin. J. Phys. Chem. B 2008,
112 (35), 10765–10768. https://doi.org/10.1021/jp800476b.
(38)

Cerón-Carrasco, J. P.; Jacquemin, D.; Cauët, E. Cisplatin Cytotoxicity: A Theoretical

Study of Induced Mutations. Phys. Chem. Chem. Phys. 2012, 14 (36), 12457–12464.
https://doi.org/10.1039/C2CP40515F.
(39)

Melchior, A.; Martínez, J. M.; Pappalardo, R. R.; Sánchez Marcos, E. Hydration of

Cisplatin Studied by an Effective Ab Initio Pair Potential Including Solute–Solvent Polarization.
J. Chem. Theory Comput. 2013, 9 (10), 4562–4573. https://doi.org/10.1021/ct400433c.
(40)

Ritacco, I.; Al Assy, M.; Abd El-Rahman, M. K.; Fahmy, S. A.; Russo, N.; Shoeib, T.;

Sicilia, E. Hydrolysis in Acidic Environment and Degradation of Satraplatin: A Joint
Experimental and Theoretical Investigation. Inorg. Chem. 2017, 56 (10), 6013–6026.
https://doi.org/10.1021/acs.inorgchem.7b00945.
(41)

Sun, Y.; Hu, L.; Chen, H. Comparative Assessment of DFT Performances in Ru- and Rh-

Promoted σ-Bond Activations. J. Chem. Theory Comput. 2015, 11 (4), 1428–1438.
https://doi.org/10.1021/ct5009119.
(42)

Adamo, C.; Barone, V. Toward Reliable Density Functional Methods without Adjustable

Parameters: The PBE0 Model. J. Chem. Phys. 1999, 110 (13), 6158–6170.
https://doi.org/10.1063/1.478522.
(43)

Antušek, A.; Blaško, M.; Urban, M.; Noga, P.; Kisić, D.; Nenadović, M.; Lončarević, D.;

Rakočević, Z. Density Functional Theory Modeling of C–Au Chemical Bond Formation in Gold
140

Implanted Polyethylene. Phys. Chem. Chem. Phys. 2017, 19 (42), 28897–28906.
https://doi.org/10.1039/C7CP05637K.
(44)

Ciancaleoni, G.; Rampino, S.; Zuccaccia, D.; Tarantelli, F.; Belanzoni, P.; Belpassi, L.

An Ab Initio Benchmark and DFT Validation Study on Gold(I)-Catalyzed Hydroamination of
Alkynes. J. Chem. Theory Comput. 2014, 10 (3), 1021–1034. https://doi.org/10.1021/ct400980w.
(45)

Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein

and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments.
J. Comput. Aided Mol. Des. 2013, 27 (3), 221–234. https://doi.org/10.1007/s10822-013-9644-8.
(46)

Olsson, M. H. M.; Søndergaard, C. R.; Rostkowski, M.; Jensen, J. H. PROPKA3:

Consistent Treatment of Internal and Surface Residues in Empirical PKa Predictions. J. Chem.
Theory Comput. 2011, 7 (2), 525–537. https://doi.org/10.1021/ct100578z.
(47) Curado, N.; Giménez, N.; Miachin, K.; Aliaga-Lavrijsen, M.; Cornejo, M.A. Jarzecki, A.A.;
Contel, M. Preparation of Titanocene-Gold Compounds Based on Highly Active Gold(I)-NHeterocyclic Carbene Anticancer Agents. Preliminary in vitro Studies in Renal and Prostate
Cancer Cell lines. ChemMedChem. 2019, under revision.

141

Chapter 6
Conclusion

6.1. Summary
In this thesis, we have successfully demonstrated that peptide building blocks can be
systematically modified to design MMP-responsive nanostructures. This approach allows control
of the morphology and charge of the nanostructures with simple changes in the amino acid
sequence, including the MMP-cleavable P6-P6’ positions. Through the systemic study discussed in
Chapter 3, we validated parameters other than the P6-P6’ sequence which affect the rate of MMPresponsiveness, such as the morphology and electrostatic charge of the nanostructures which can
help achieve MMP specificity. In Chapter 2, we analyzed over 40 different systems described in
the literature and found multiple examples that confirm our conclusion. In addition, the systematic
approach to peptide design allows us to control the morphology of the post-enzymatically cleaved
product, or the mode of response. We demonstrated that amyloid-like fiber forming products
causes selective cytotoxicity to cells that overexpress MMPs and disintegrating products are nontoxic and continues to degrade into amino acids. As discussed in Chapter 2, the modes of MMPresponsiveness can influence multiple factors such as the rate of payload release and its efficacy.
Lastly, we demonstrated that peptide nanostructures can be used to encapsulate anti-cancer
organometallic compounds that are otherwise too hydrophobic to be administered in vitro or in
vivo. During this investigation, it is imperative that the self-assembly of the peptide nanostructures
are reproducible each time, which can be significantly altered by trace amounts of TFA salts that
are left from peptide synthesis but are often neglected. Through a number of techniques, we
demonstrated that peptide self-assembly is significantly altered by TFA which could explain the
vastly different self-assembly behavior of a same peptide molecule reported in literature.
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In summary, we have addressed the questions asked in the beginning of Chapter 1 through
experimental results and literature analysis. As demonstrated in Chapters 2 and 3, specificity
towards MMPs can be achieved by nanomaterials by 1) using optimized P6-P6’ sequence for the
target MMP, 2) designing morphologies that are similar to the native substrate of the target MMP,
and 3) by mis-matching the short-range electrostatic interaction of the MMP and nanomaterial.
The three criteria can be readily modified in peptide nanostructures by small changes in amino
acids, unlike other materials which require a different a different building block (ie. negatively
charged phosphatidylglycerol vs. neutral phosphatidylethanolamine).
Literature analysis showed that MMP-responsive nanomaterials can improve the efficacy
of anti-cancer treatments based on the modes of response. The efficacy of the drugs loaded in
MMP-responsive materials are not always improved by increasing toxicity or tumor reducing
ability, but by making the treatment more selective and causing less systematic damage. We
demonstrated that the modes of response can also be controlled using peptide nanostructures to
form cytotoxic fibers or non-toxic products. In addition, we showed proof-of-concept in which
peptide nanostructures can be used to encapsulate metallodrugs which can potentially increase the
efficacy of these drugs by making them more soluble and selective towards cells that overexpress
MMP.

6.2. Future work
The work of MMP-responsive peptide nanostructures will carry on testing if the efficacy
of the metallodrugs can be improved in vitro. Currently, we are characterizing drug-loaded peptide
nanocarriers to study the stability of the nanocarrier and the rate of MMP-responsiveness and drug
release. Our plan is to incorporate other sequences such as 3 AK which can have additional
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therapeutic effects. The in vitro studies will be conducted in cell lines with high and low expression
of MMP-9 which will be quantified by ELISA. In addition, the stability of the peptides will be
tested in human plasma which can help to predict the half-life of the drug-loaded peptide
nanocarriers when administered in vivo. This work will continue as a joint-collaboration between
the Contel group at Brooklyn College and the Ulijn group at ASRC.
Due to the versatility of the peptide nanostructures, and the highly disease relevant MMP
target, many collaborative interests have sprung out from this research. For example, MMPs are
expressed in mice with multiple sclerosis that break down the blood-brain-barrier. By treating the
mice with one of AK peptides loaded with therapeutic payloads, the fibers can localize at the site
of MMP overexpression and build up the blood-brain-barrier and simultaneously release the
therapeutic agents. Other research groups have shown interest in modifying the terminal Phe to
Tyr residue which can be used to conjugate radioactive iodine (131I) for diagnostic imaging.
Another research group is interested in using the MMP-response peptides as capsules to
encapsulate growth factors that can simulate cell differentiation. The possible applications of these
MMP-responsive peptide nanostructures are enormous, and while they may not be successful for
every application, the design principle behind the peptides can be applied to all MMP-responsive
nanomaterials.
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